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ABSTRACT 
Vanessa González-Pérez 
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in 
C. elegans and mammalian cells 
(Under the direction of Adrienne D. Cox, PhD) 
 
 Molecularly targeted inhibitors are typically screened in cell-based assays for 
activity and target selectivity. However, early in vivo evaluation may improve 
characterization of specificity and/or detection of toxicity or off-target effects. In this 
dissertation, I describe use of the nematode C. elegans as an in vivo model to 
characterize both on- and off-target activity of novel putative Ras/Raf interaction 
inhibitors. In mammals, the Ras>Raf>MEK>ERK signaling cascade promotes 
cellular proliferation.  Its aberrant activation is associated with oncogenesis and it is 
an attractive pharmaceutical target.  In C. elegans, this pathway is highly conserved 
and regulates vulval development.  Constitutive pathway signaling results in an 
easily scored Multivulva (Muv) phenotype that provides an accurate in vivo readout 
for activity of inhibitors targeting the pathway. I therefore validated the Muv 
phenotype for evaluation of the activity and specificity of known and novel pathway 
inhibitors, beginning with the well-characterized MEK inhibitor U0126.  I then 
characterized its response to small molecule members of the MCP family of putative 
Ras/Raf interaction inhibitors.  Analysis of a C. elegans strain expressing activated 
Ras (worm ortholog, LET-60) showed that MCP110 and MCP116 act downstream of 
Ras, causing significant dose-dependent reduction of Muv. Analysis of strains 
  iv 
genetically activated downstream of Ras showed that these compounds act 
upstream of the ETS-like transcription factor (LIN-1) and the MAP kinases, MEK-2 
and MPK-1. The best available strain expressing activated Raf (LIN-45AA) was 
unable to distinguish whether these compounds act at the level of Ras or of Raf, and 
may not be Ras-independent. I then turned to cell-based assays using NIH 3T3 
mouse fibroblasts, and showed for the first time that MCP110 dose-dependently 
disrupts the physical interaction between Ras and Raf and impairs Ras recruitment 
of Raf to cellular membranes. I also narrowed the affected protein:protein interaction 
to that of Ras with the Ras binding domain (RBD) of Raf. Finally, I identified specific 
NPYR-like off-target effects of MCP compounds in C. elegans. Thus, C. elegans is a 
valuable in vivo genetic system to characterize on- and off-target activity of inhibitors 
targeting the Ras>Raf>MEK>ERK pathway and may be useful for other novel 
therapeutics.  
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CHAPTER I 
 
 
INTRODUCTION 
 
 
Molecularly targeted therapeutics    
 
Increased understanding of the molecular events underlying human diseases, 
coupled with the development of novel techniques and equipment to increase 
throughput for identification of inhibitors of critical molecular drivers of disease, have 
allowed rapid growth in the area of molecularly targeted therapeutics.  Each year 
more drug screening approaches are utilized and hundreds of thousands of 
chemical entities undergo preclinical and clinical evaluation with the goal of 
becoming successful drug treatments. The drug discovery process is long and 
costly, where more battles are lost than won, and where the increasing amount of 
knowledge in each disease only becomes more complex than the day before. 
In this chapter I aim to offer a brief summary of the drug discovery process for 
treatment of Ras-dependent cancers, the elements involved in it and some 
examples of validated targets and some therapeutics against them.  I will then 
describe the background underlying the search for targeted therapeutics aimed at 
blocking the interaction of the small GTPase Ras with one of its key effectors, the 
serine/threonine kinase Raf.  Together, these will serve as an introduction to my 
dissertation research that is described in subsequent chapters. 
 
   2 
Target identification and validation  
 
Identifying appropriate anti-cancer targets is an ongoing quest for many 
researchers seeking to develop novel therapeutics for cancer treatment.  Over 
decades, a variety of genetic lesions have been identified as the driving forces for 
the development of cancers (Ali and Sjoblom, 2009; Liu, 2008), and as a 
consequence they have become the focus for the development of molecularly 
targeted therapeutics. Nowadays, the availability of  genomic and proteomic 
databases have provided endless sources to identify novel genes in a more rapid 
and efficient way than before. The elucidation of these genetic lesions, which can 
include the activation of oncogenes or the silencing of tumor suppressor genes, are 
important not only for the discovery of novel therapeutics but also for the early 
detection of disease (Midorikawa et al., 2009). However finding genes associated 
with cancer is just the first step. For example, not all genes associated with cancer 
are ideal candidates for the subject of a high-throughput screen. First, the gene’s 
disease relevance to the disease must be validated, followed by analysis of its 
molecular properties that would allow a given target of interest to be targeted by a 
chemical entity. 
A key question for target selection is if the target is sufficient and/or 
necessary for the onset and progression of a particular malignancy. For example, in 
a given sample of tumor tissue it is possible to detect many genetic lesions. 
However, only a subset of those genes would be sufficient and/or necessary for the 
onset or maintenance of a tumor (i.e., would be “driver” mutations rather than 
“passenger” mutations). Another important aspect of target selection is to 
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understand it in the context of cellular signaling networks and its biological role in the 
progression of a disease.  The latter is of great importance because we want to 
target specific genes or signaling networks, without interfering with other pathways 
that may be essential for proper cell function. Target selection and validation 
nowadays often follows the “omics” methods of gene transcription profiling 
(‘transcriptomics’), protein expression profiling (‘proteomics’), metabolic pathways 
(‘metabolomics’), protein glycosylation (‘glycosilomics’), protein–protein interactions 
(‘interactomics’) and systems biology in silico (Anders and Vielhauer, 2007).  In 
combination with classical preclinical evaluation methods examining proteins 
individually, many potentially relevant targets have been discovered, validated and 
subjected to drug screens. However, a target is only truly validated when inhibitors 
of it reach the clinic (Colombo and Moll, 2008), and more candidate inhibitors fail 
than succeed.  
Over the years various approaches have been used for the selection of 
targets for drug development. Some targets surface as a result of a group’s 
independent research in the function of specific genes, proteins and/or pathways. 
Others have been discovered as the result of data mining of the now enriched 
genomic databases and genome profiling results. Additional strategies that have 
also proved to be successful for the identification of therapeutic targets for example 
in hepatocellular carcinoma, and that can be also applicable to various other 
malignancies, include:  high throughput genetic analysis, comprehensive expression 
analysis, gene copy number analysis, promoter arrays and tiling arrays (Midorikawa 
et al., 2009). One new method of choice is gene silencing by interference by RNA 
   4 
(RNAi).  RNAi takes advantage of a naturally occurring mechanism by which cells 
regulate the expression of genes at the post-transcriptional level, and introduces a 
new era in loss-of-function experiments, allowing for the rapid measurement of the 
phenotype observed upon target expression abrogation (Colombo and Moll, 2008). 
RNAi results in the knockdown or silencing of a gene by the binding of short-double 
stranded RNAs molecules, also known as small-interfering (siRNAs), to their 
complementary mRNA, which leads to mRNA degradation. 
Currently, RNAi is the most widely used method for the specific and rapid 
inhibition of gene expression and its high efficiency, strong potency, fast turnaround 
of results and its potential to be developed into HTS have made it the method of 
choice for both target identification and validation.  Another advantage of using RNAi 
is that it can be used at different stages of the drug discovery process starting at 
HTS for initial target identification, in in vitro biological assays for in-depth analysis of 
gene function in vitro to in vivo models for the analysis of gene function in animals 
(Lavery and King, 2003) . 
 Lately, RNAi screens have proved to be a popular approach to confirm known 
genetic lesions as well to identify novel genetically altered targets in patient samples. 
A recently reported screen of primary leukemia cells from 30 patients, by RNAi, 
identified targets that are critical to survival of the malignant cells. Most of these 
targets were known and widespread, like activating mutations in K-RAS, N-Ras and 
JAK2, FLT1, CSF1R and PDGFR. Less expected were ROR1, EPHA4/5 and 
LMTK3. Novel somatic mutations in the thrombopoietin receptor were also identified 
(Tyner et al., 2009).  However, an important caveat with such a widespread use of 
   5 
RNAi is that because it prevents expression of the entire protein, it does not mimic 
very well the consequences of drug action, that do not block expression but do 
impair specific functional aspects.  Thus, RNAi has the same downside as described 
below for gene knockouts, in that it changes stoichiometry in ways that 
pharmacological agents do not.  This can be very important for multi-functional 
proteins, and especially for scaffolding proteins, as is relevant in Chapter III. 
 For many years, oncogenic Ras has been considered an attractive target for 
anti-cancer therapeutics based on its status as the most frequently mutated 
oncogene in human cancers (Bos, 1989).  It was additionally important to validate its 
ability to regulate cancer-related biological readouts like anchorage-independent 
growth or tumor growth in xenograft models, as will be discussed below.  Recently, 
RNAi has been used to validate which downstream effectors are needed by Ras, 
and this helped confirm a role for the serine/threonine kinase, Raf.  There was also a 
need to validate Raf itself, as a critical downstream effector of Ras (see figure 1. 5 
and 2.1), as a potential target for anti-cancer therapeutics. Since Raf phosphorylates 
MEK on serines 218 and 222, a MEK mutant in which these serines are substituted 
by alanines (MEK218A/222A) cannot be activated by Raf (Arboleda et al., 2001). 
This MEK dominant negative mutant should block the Raf/MEK/ERK pathway, either 
by sequestering Raf or by sequestering ERK and blocking their wild-type activity 
(Lyons et al., 2001; Zheng and Guan, 1994).  Their observations showed the inability 
of cells harboring oncogenic Ras, but also expressing dominant negative MEK 
mutants, to support anchorage-independent growth, thus correlating with the 
reduction in MEK activity.   Moreover they were also able to detect that the MEK 
   6 
dominant negative mutant was able to block tumor progression in mice (Lyons et al., 
2001). These results were part of the evidence used to validate Raf as a therapeutic 
target and thus further strengthened the need to pursue drug discovery programs to 
find inhibitors of Raf. 
Proper validation is critical for the drug discovery process, since 
understanding the role of the putative target will become key in the design of the 
drug screen, the selection of the screen endpoints and perhaps can aid in the 
understanding of the mechanism of action of chemical compounds that are 
potentially interacting with the selected target.  
 
Small molecule compound screens  
 
 The purpose of a drug screen is to find small molecules that could serve as a 
lead compound for the development of a drug.   Most commonly, small molecule 
libraries are browsed using high throughput screens (HTS). HTS are meant to 
monitor thousands of molecules per day, and the success of the screening platform 
strongly relies on the selection of the appropriate small molecule compound library in 
combination with robust assays to measure the selectivity and potency of the 
compounds being screened against the target of interest. Besides selecting the most 
appropriate system for the screen, it is also very important to take into consideration 
the class of compounds in a chemical library. The decision can be made based on 
the drug-like characteristics of the library, information that can be assessed from 
records of previous computational modeling analysis of the molecules or simply by 
the type of active lead candidates selected in the past from the same library. For 
example, for gene families such as kinases (Stahura et al., 1999) and G-protein- 
   7 
coupled receptors (Balakin et al., 2002; Stahura et al., 1999), there are hundreds of 
known active compounds that can be used as starting points for a ligand-based 
design.  It is also important to take into consideration the physicochemical properties 
that are necessary to increase the likelihood of oral bioavailability as they have been 
formalized into Lipinski’s “rule-of-five” (Lipinski et al., 2001). Bioavailability is one of 
the most important pharmacokinetic properties of drugs, because compounds with 
good bioavailability will be able to circulate throughout the body and retain activity. 
In vitro biochemical assays possess an advantage over cell-based or in vivo 
assays because there are no concerns about the cell permeability or potency of 
compounds. Another advantage of in vitro assays is that they can be performed at 
higher drug concentrations, which can help in the identification of novel chemical 
classes (Walters and Namchuk, 2003).  On the other hand, cell-based systems can 
be employed to complement in vitro data, providing greater confidence in compound 
activity in an intact biological system (Horrocks et al., 2003). An advantage provided 
by cell-based assays is that cell lines can be engineered to exogenously express or 
over-express a target of interest, thus making the screening platform more sensitive 
or powerful to select active compounds against the desired target. Several readouts 
are available for high-throughput cell-based assays. Among these are: i) reporter 
assays that link the promoter of the gene target to an appropriate reporter gene and 
ii) fluorescently modified antibodies in combination with high-throughput microscopy, 
that help monitor changes in particular aspects of cell morphology or function 
(Horrocks et al., 2003) and proliferation, cytotoxicity, secretion, translocation, 
redistribution, protein expression and enzyme activity among others (Johnston, 
   8 
2002). The use of these techniques has allowed the miniaturization of many cell-
based assays and as a consequence increased the throughput of the screens.  
Before performing an HTS, there are many important aspects to take into 
consideration, such as selecting the appropriate cell model, selecting the appropriate 
control to reduce the selection of false-positives and false-negatives, being able to 
produce sufficient cells for the HTS, the optimization for the assay for the drug 
screen and being able to capture a reproducible signal from the assay. All of the 
aspects mentioned before, are critical for the success of a cell-based HTS. Overall, 
cell-based assays can provide significant information on the nature of the 
pharmacological activity of a compound.  Once the primary screen yields candidate 
compounds (hits), they undergo further testing to test their activity and target 
specificity to fewer active hits (leads) that can be further optimized and validated in 
preclinical models before advancing into clinical evaluation.    
  
Ras proteins: anticancer targets regulated by GTP/GDP cycling and membrane 
localization  
Ras (Rat sarcoma) is the founding member of a large, evolutionarily 
conserved superfamily of small GTPases. Ras family members are subdivided into 5 
major branches, based on sequence and functional similarities: Ras, Rho, Rab, Ran 
and Arf (Wennerberg et al., 2005) (Figure 1.1).  Ras proteins have been studied for 
the past 30 years and they are now known to participate in a variety of important 
biological functions such as regulation of gene expression, cell survival, actin 
organization and cell cycle progression (Figure 1.2). 
   9 
 Ras is synthesized in the cytosol and post-translationally modified to be 
recruited to the plasma membrane and endomembranes (Chiu et al., 2002; Hancock 
et al., 1990). At the plasma membrane, Ras cycles between inactive (GDP-bound) 
and active (GTP-bound) states (Figure 1.3A). Guanine nucleotide exchange factors 
(GEFs) positively regulate Ras proteins by stimulating the exchange of GDP for 
GTP, whereas GTPase activating proteins (GAPs) negatively control Ras family 
members by catalyzing the hydrolysis of GTP, causing them to become GDP-bound 
and inactive (Bernards and Settleman, 2004; Boguski and McCormick, 1993; 
Giglione et al., 1997). The structural differences between GDP- and GTP-bound 
states of Ras are localized to two regions of the protein, switch I (Ras residues 32-
38) and switch II (residues 59-67), with the GTP conformation having increased 
affinity for downstream effectors (Figure 1.3B) (Mitin et al., 2005). Ras effectors bind 
through the “effector domain” flanking residues 25-45 (Figure1.4) (Vojtek and Der, 
1998) (White et al., 1995) and in fact, one requirement for a given protein to be 
designated as a Ras effector is that it interacts preferentially with GTP-bound, active 
Ras compared to GDP-bound, inactive Ras. Direct disruption of the Ras/Raf 
interaction by specific protein:protein interaction inhibitors may therefore be the 
result of inhibitor binding to the Ras effector domain. 
Ras proteins are synthesized in the cytosol where they are inactive, but 
immediately after synthesis they become lipid-modified and targeted to the plasma 
membrane. At the plasma membrane, GEF proteins are localized in response to 
extracellular stimuli, which in turn activate Ras to become GTP-bound and interact 
with effectors to transmit its signals.  Oncogenically mutated Ras is chronically GTP-
   10 
bound and independent of upstream signals, but still requires correct localization to 
the plasma membrane for biological activity, presumably so it can promote activation 
of its downstream effectors such as Raf. 
Ras association with the plasma membrane is mediated by a series of steps 
involving the modification of the carboxyl termini (CAAX motif) of all Ras proteins, 
where C= cysteine, A= aliphatic amino acid and X= terminal amino acid. This 
sequence drives the recognition of the Ras protein by the enzyme farnesyl 
transferase (FTase), which adds a 15-carbon (C15) farnesyl isoprenoid lipid to the 
cysteine of the CAAX motif (Reiss et al., 1990) to start the targeting to the plasma 
membrane. This step is followed by proteolytic cleavage of the -AAX residues by the 
endopeptidase, Rce1 (Ras and factor converting enzyme) (Boyartchuk et al., 1997; 
Kim et al., 1999; Otto et al., 1999), and carboxyl methylation of the now terminal 
cysteine, by isoprenylcysteine carboxyl methyltransferase (Icmt) (Dai et al., 1998; 
Hrycyna et al., 1991).   In addition to farnesylation, a second signal is need to target 
Ras to the plasma membrane. The three Ras isoforms that are ubiquitously 
expressed in the cell: H-Ras, K-Ras and N-Ras and they share sequence homology 
between amino acids 1-165, but they have distinct regulatory sequences for their 
efficient positioning in the plasma membrane (Apolloni et al., 2000; Choy et al., 
1999; Hancock, 2003; Hancock et al., 1990).  It is noteworthy that these post-
translational modifications are not only necessary for Ras localization to the plasma 
membrane and promotion of its activity but are also they are necessary to propagate 
the signals of oncogenic Ras in cancer cells. As will be discussed below, given the 
important role of enzymes mediating Ras plasma membrane localization in the 
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activation of Ras, they soon were considered attractive targets to generate novel 
anti-cancer therapeutics against Ras-driven malignancies.  The lipid modification 
status also may influence the interactions of Ras with Raf by dictating the specific 
membrane domains for Ras and Raf localization (Fischer et al., 2007; Thapar et al., 
2004). Finally, targeting Raf to the plasma membrane by the addition of the Ras C-
terminal domain, including both CAAX and immediate upstream sequences, is 
sufficient to cause constitutive activation of Raf signaling (Leevers et al., 1994; 
Stokoe et al., 1994), indicating the importance of the Ras/Raf interaction for Raf 
activation. 
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Figure 1.1 Ras belongs to a superfamiy of small GTPases. All five branches: 
Ras, Arf, Rho, Ran and Rab share biochemical mechanisms and functional 
similarities.  Adapted from: Wennerberg et al. (2005) J Cell Science 117:1301 
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Figure 1.2 Ras acts as a signaling node 
Ras transduces activating signals from upstream extracellular cues into the cell. In 
turn Ras acts as a signaling node to activate downstream effectors that regulate a 
wide variety of biological functions. 
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Figure 1.3 Ras cycles between an “ON” and “OFF” state 
A) Regulation of Ras:  Guanine nucleotide exchange factors (GEFs) stimulate the 
exchange of GDP for GTP (Ras-GTP = active conformation), whereas GTPase 
activating proteins (GAPs) catalyze the hydrolysis of GTP (Ras-GDP = inactive 
conformation).  B) Ras binding to GTP causes a conformational change in the 
effector binding domain that facilitate its interaction with and activation of 
downstream effectors to then regulate a variety of biological outcomes. 
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Figure 1.4. Ras protein effector domains 
The effector domain, including core residues 32-40 (bold fonts) and flanking 
residues 25-45 (green box), is also known as switch I, because it switches 
conformation depending on whether Ras is in the active, GTP-bound state or the 
inactive, GDP-bound state.  When GTP-bound, the effector loop is more solvent-
exposed and therefore more available for interactions with effectors such as the 
cytoplasmic Raf serine/threonine kinases, which bind to Ras through their Ras 
binding domains (RBDs).  The effector domain sequences of mammalian Ras 
proteins are closely conserved with that of the C. elegans Ras ortholog, LET-60. 
Sequence alignments were performed in ClustalW2 software 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html), were aligned residues marked  (*) 
are identical, (:)conserved substitutions and (.)semi-conserved substitutions. 
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Ras is genetically altered in cancer  
Genetic lesions in Ras are present in about 30% of all human cancers, with 
higher incidence in pancreas (90%), colon (50%), thyroid (50%), lung (30%) and 
melanoma (25%) (Bos, 1989) (Malumbres and Barbacid, 2003). Point mutations in 
residues 12, 13 or 61, turn Ras proteins into active oncogenes; mutations at these 
positions makes Ras insensitive to negative regulation by GAP proteins, therefore 
leaving the protein constitutively activated (Bos, 1989) (see Fig 1.6). The biological 
role of oncogenic Ras was initially measured by its ability to transform established 
rodent fibroblast cell lines leading to their growth in soft agar and tumorigenesis in 
nude mice (Clark et al., 1995).  Aberrant Ras activity leads to the de-regulation of 
numerous processes in the cell, such as cell proliferation, cell survival, apoptosis, 
migration, cell adhesion that in turn can contribute to cell transformation, invasion 
and metastasis (Campbell and Der, 2004).   
As previously stated, Ras acts as a signaling node that transmits many 
upstream signals into many downstream signals (Figure 1.2). Ras activity can also 
be mis-regulated by some of its upstream regulators, and not only by mutations in 
Ras itself. One mechanism by which this happens is overexpression of the 
epidermal growth factor receptor (EGFR), for example in colorectal, pancreatic, lung 
and non-small lung cell cancer (Roberts and Der, 2007). On the other hand, 
downstream of Ras there are multiple effectors that contribute to transducing diverse 
biological consequences caused by oncogenic Ras, but for the purposes of this 
dissertation I will focus my discussion on the deregulation of the 
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Ras>Raf>MEK>ERK signaling pathway, initiated by signals from oncogenic Ras or 
Raf, and their biological consequences in cancer. 
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Figure 1.5. Simplified overview of Ras effector signaling pathways. Of the many 
Ras effectors ( >20 to date), the best studied are the phosphatidylinositol 3-kinases 
(PI3-kinases), Ral guanine nucleotide exchange factors (RalGEFs) and the 
serine/threonine Raf kinases (A-Raf, B-Raf and Raf-1), whose combined signaling 
networks contribute to biological outcomes in the cell like trafficking, survival and 
growth among others. 
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Figure 1.6  Oncogenic Ras regulation and biological effects.  A) Point mutations 
in residues G12V, G13E or Q61L render Ras insensitive to GAP negative regulation 
and as a result oncogenic Ras (green starburst shape), remains constitutively 
activated. B) Constitutive activation of many Ras effectors leads to oncogenic 
outcomes. 
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Role of the Ras>Raf>MEK>ERK pathway and its activation in cancer  
 
Ras has many downstream effectors that contribute to amplifying Ras 
signaling for normal function and disease-related events. Among the best studied 
downstream effectors of Ras that also contribute to its transforming activity are the 
phosphatidylinositol 3-kinases (PI3-kinases), Ral guanine nucleotide exchange 
factors (RalGEFs) and the serine/threonine Raf kinases (Raf-1, A-Raf and B-Raf)  
(Figure 1.5).  Here I will focus on the Ras>Raf>MEK>ERK MAPK pathway and its 
role in cancer. 
Classic activation of the MAPK cascade occurs following ligand binding to a 
receptor tyrosine kinase such as EGFR at the cell surface, but additional receptors 
such as integrins, serpentine receptors, heterotrimeric G-proteins and cytokine 
receptors can also activate this signaling cascade (Friday and Adjei, 2008).   In an 
oncogenic context, overexpression or mutation of members of the EGFR family is a 
driving factor for numerous cancers including pancreatic, lung, head and neck 
squamous cell cancer, colorectal and glioblastoma (Khazak et al., 2007). Such 
alterations are a source for the deregulation of Ras activation and therefore de-
regulation of its effector pathways, thus adding another layer to the complex 
signaling network that can contribute to the onset of cancer and to its progression 
and maintenance. 
 Ras activation is the first step in the activation of the Ras>Raf>MEK>MAPK 
cascade, followed by Raf (A-Raf, B-Raf, or Raf-1) activation, which is recruited to the 
cell membrane through binding to Ras. Activation of Raf involves several de-
phosphorylation and phosphorylation steps.  Once recruited to the plasma 
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membrane by interaction with active Ras, Raf is activated by phosphorylation of 
residues in its kinase domain to unfold the protein from its inactive conformation and 
make the kinase catalytic activity available to be activated and to interact with 
downstream effectors  (Figure 1.7).  Activation signals from EGFR, then 
subsequently Ras and Raf leads to the activation of the mitogen-activated protein 
kinase-kinases (MAPKK), MEK1 and MEK2. MEK1/2 then phosphorylate and 
activate the mitogen-activated protein kinases (MAPKs), ERK1/p44 and ERK2/p42 
(Hamad et al., 2002; Kyriakis et al., 1992). In turn ERK has multiple targets including 
transcription factors Elk-1 and Ets1/2, ribosomal protein kinase p90RSK1, MNK1/2, 
etc., whose cellular functions are to regulate cell proliferation, survival and mitosis by 
regulating transcription and translation respectively (Friday and Adjei, 2008). This 
pathway plays a major role in both normal and aberrant EGFR signaling by 
transducing signals through Ras and Raf.  However, some components of the 
pathway can be mutationally activated and therefore render the pathway active 
independent of EGFR or other upstream inputs. 
 Additional studies of the Ras>Raf>MEK>ERK pathway have revealed that Ras 
is not the only protein found mutated in this pathway, since the serine/threonine 
kinase Raf also is found to be mutationally activated. A single base substitution, from 
valine (V) to glutamic acid (E) in codon 600 (V600E), was identified in the catalytic 
domain of B-Raf (Davies et al., 2002). B‐Raf has been found to be mutated in many 
types of cancer and is commonly found in tumors such as melanoma (~66%), 
colorectal cancer (~15%), thyroid cancer (~40%) and gliomas (11%), (Davies et al., 
2002; Garnett and Marais, 2004; Young et al., 2009).  However, oncogenically 
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mutated Ras or Raf are generally mutually exclusive among cancer patients (Davies 
et al., 2002), suggesting that they have overlapping functions.  Additional studies 
confirmed that expression of B-Raf(V600E) in NIH3T3 cells and murine melanocytes 
stimulates constitutive ERK signaling, induces proliferation and transformation, and 
allows these cells to grow as tumors in nude mice (Davies et al., 2002; Wellbrock et 
al., 2004), therefore supporting B-Raf V600E) as an mutationally activated 
oncogene. Once the oncogenic potential of B-Raf was validated by its ability to 
induce transformation and tumor formation in mice, it was then examined to test its 
potential as a target for anti-cancer therapeutics.  Soon after, studies with RNA 
interference and a multikinase pharmacological inhibitor demonstrated that depleting 
oncogenic B-Raf in cancer cells reduced ERK activity, inhibited proliferation, and 
induced apoptosis (Karasarides et al., 2004), ultimately showing the potential of B-
Raf as a therapeutic target for tumors harboring B-Raf mutations. 
 Early studies aimed at characterizing the Ras>Raf>MEK>ERK signaling 
cascade showed that constitutive activation of MAPK is sufficient and necessary for 
cell differentiation and proliferation of PC12 and NIH3T3 cells, respectively (Cowley 
et al., 1994).  Soon after altered MEK proteins were implicated in carcinogenesis. 
First, engineered mutants with alterations in the key regulatory serine residues 
showed their ability to transform NIH 3T3 cells (Mansour et al., 1994).  More 
recently, gain-of-function mutations have been found in MEK1 in ovarian (Estep et 
al., 2007) and lung adenocarcinomas (Marks et al., 2008).  Functional 
characterization of the mutant MEK1(K57N) found in lung adenocarcinomas showed 
that cells transfected with this mutant displayed increased levels of ERK 
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phosphorylation that was sensitive to inhibition by the MEK1 inhibitor AZD6244 
(Marks et al., 2008; Yeh et al., 2007). Altogether, this showed increasing evidence of 
additional clinically relevant targets besides Ras for the inhibition of the 
Ras>Raf>MEK>ERK pathway for anti-cancer therapeutics.  
The high incidence of oncogenic Ras and Raf mutations and the dependency 
on Raf to transduce many of the signals caused by Ras activation, as well as the 
finding of altered MEK and increased MAPK signaling in some but not all types of 
cancer with upstream activation of the pathway has led to many studies attempting 
to target these proteins (Wagner and Nebreda, 2009). For this dissertation, I will 
focus on discussing inhibitors of Ras or Raf activity and inhibitors of Ras/Raf 
interactions. 
 
 
Inhibitors of the Ras>Raf>MEK>ERK pathway 
 
Ras inhibitors  
 
Given that signaling caused by oncogenic Ras quickly became attractive for 
the design of anti-cancer therapeutics, is not surprising that the first efforts to inhibit 
the Ras signaling pathway focused on targeting Ras activation. Efforts to target the 
active GTP-bound form of Ras would be optimal but have failed, possibly because of 
the very high (picomolar) affinity of GTP for the GTPase (Wittinghofer and 
Herrmann, 1995).  One study (Fischbach and Settleman, 2003) showed that it was 
possible to target mutationally active Ras-GTP with nucleoside diphosphate kinase 
in vitro, but this approach has also not led to any clinically useful entities.   Therefore 
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other attempts to target Ras have focused on its subcellular localization or its 
downstream targets, particularly kinase targets that are thought to be “druggable”. 
As described above, Ras activation requires its association with the plasma 
membrane, and its interaction with positive modulators (GEFs) to become activated 
to transmit downstream signals (Der and Cox, 1991).  One of the first steps required 
for translocation of Ras to the plasma membrane involves the addition of a farnesyl 
lipid to the CAAX motif of Ras by the enzyme farnesyltransferase (FTase). By 
helping wild type Ras to be targeted to the correct cellular localization, this lipid 
modification is known to be necessary for Ras transforming activity (Hancock et al., 
1990; Kato et al., 1992), making FTase an attractive target to prevent oncogenic Ras 
activity (Kohl, 1999; Lerner et al., 1997). Because Ras modification by FTase is 
necessary for its activation, one approach to inhibit the pathway was to target 
FTase, with the expectation of preventing active Ras from localizing to the plasma 
membrane and subsequently blocking aberrant activation of downstream effectors.  
Several farnesyltransferase inhibitors (FTIs) have been shown to inhibit Ras 
farnesylation in cell cultures and reverse the transformed phenotype caused by 
oncogenic Ras in vitro and in xenograft models (James et al., 1993; Kohl, 1999; Kohl 
et al., 1993).  Given the positive results in preclinical models, some of these FTIs 
reached clinical trials.   Further evaluation of FTIs, showed they could block the 
farnesylation of all Ras isoforms in in vitro enzyme assays in which only Ras and 
FTase were present, but failed to effectively block the isoprenoid modification and 
membrane association of K-Ras and N-Ras in cells (James et al., 1995; Lerner et 
al., 1997). Soon after it was understood that in the presence of FTIs in the cell, N- 
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and K-Ras, but not H-Ras undergo alternate prenylation by the enzyme geranyl 
geranyltransferase I (GGTase I) (James et al., 1995; Lerner et al., 1997; Zhang et 
al., 1997) . Further evaluation of FTIs showed that they are not truly anti-Ras drugs 
since they had preclinical antitumor activity against a wide array of tumors, not all 
harboring Ras mutations, and their activity did not require inhibiting Ras 
farnesylation (Cox and Der, 2002).  
The failure of FTIs to be effective anti-Ras inhibitors led many researchers to 
try other approaches to inhibit Ras signaling to the Ras>Raf>MEK>ERK pathway, 
among them to target downstream effectors of Ras like Raf and perhaps Ras/Raf 
interactions, as will be described in Chapter III.  However, there are ongoing studies 
of other inhibitors of Ras membrane localization that suggest this may be an 
effective way of targeting Ras for cancer treatment.  In particular, the “Ras inhibitor” 
salirasib (also called FTS, for farnesyl-S-thiosalicylic acid (Elad et al., 1999; Gana-
Weisz et al., 1997; Haklai et al., 1998; Marciano et al., 1995)) has been reported to 
disrupt the interaction of H-Ras with its chaperone galectin-1 (Paz et al., 2001), itself 
an oncogene, and of K-Ras with its chaperone galectin-3 (Elad-Sfadia et al., 2004).  
This is thought to occur because FTS mimics the farnesyl group of Ras (Blum et al., 
2008).  The consequences of these disruptions include dislodging Ras from the 
plasma membrane and also decreased signaling to phospho-ERK as well as 
reversal of transformed growth in vitro and in vivo (Rotblat et al., 2008).  An 
impressive list of Ras-driven tumors has been shown to be susceptible to salirasib 
(Blum et al., 2008), and the results of two clinical trials of salirasib reported last 
summer (ASCO abstracts 2009) also suggest the possibility that this means of 
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interfering with Ras membrane targeting and biological functions could someday 
become a useful cancer treatment. 
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Figure 1.7 Raf activation is a multistep process 
Upon interaction with Ras, Raf undergoes conformational changes and a series of 
phosphorylation and dephosphorylation steps to render Raf in an open conformation 
that is able to interact with and phosphorylate its downstream target, MEK. 
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Raf inhibitors 
 
It is well documented that the Ras>Raf>MEK>ERK signaling pathway 
includes more than one oncogene, since the serine/threonine kinase B-Raf also is 
found to be mutationally activated in a smaller set of cancer types like malignant 
melanoma, thyroid cancer and colorectal cancer among others (Davies et al., 2002; 
Garnett and Marais, 2004). It is noteworthy that the presence of oncogenic Ras or 
Raf are generally mutually exclusive thus making Raf an additional attractive and 
relevant target for anti-cancer therapeutics of this pathway. 
One putative Raf kinase inhibitor, BAY43-9006 (sorafenib) (Lee and 
McCubrey, 2003; Lyons et al., 2001), which had promising pre-clinical results and 
bioavailability, advanced to clinical trials.  Soon, after additional characterization of 
BAY 43-9006, it was uncovered that this compound had additional activity towards 
the pro-angiogenic vascular endothelial growth factor receptor (VEGFR)-2 and -3, 
and additional receptor tyrosine kinases also involved in tumorigenesis (Wilhelm et 
al., 2006; Wilhelm et al., 2004). In a phase I clinical trial involving BAY 43-9006, the 
partial response of patients with renal cell carcinoma (RCC), whose tumors have 
high VEGFR expression, led to additional testing of this inhibitor in this selected 
group of patients. Assessment of BAY 43-9006 in RCC patients eventually led to its 
approval for the treatment of patients with advanced RCC (Khazak et al., 2007; 
Wilhelm et al., 2006).  Despite the unexpected activity of BAY 4309006 against other 
kinases, the observations made through the evaluation of this compound suggested 
that angiogenesis via targeting VEGFR may be the major therapeutic activity of the 
drug in these tumors, and that BAY 43-9006 also interrupts proliferative signaling 
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arising upstream of Ras (Khazak et al., 2007). Given the additional activity of BAY-
43-9006, it was soon known that in order to target Raf activity other inhibitors 
needed to be isolated and evaluated for better specificity against Raf. 
 Additional Raf kinase inhibitors have successfully gone through preclinical 
and/or clinical evaluation. Some examples of these are RAF-265 and PLX-4032. 
Briefly, PLX-4032 is an orally bioavailable kinase inhibitor developed by Plexxikon 
and Roche. Characterization of PLX-4032 has shown potent inhibition of wild-type 
and mutant B-Raf V600E and also showed significant tumor growth delay, including 
tumor regression without evidence of toxicity (Tsai et al., 2008). PLX-4032 has 
entered Phase I clinical trials for melanoma patients in which occurrence of B-Raf 
V600E has been confirmed (Khazak et al., 2007).  One additional Raf kinase 
inhibitor is Raf-265, a compound originally developed by Chiron and Novartis.  Raf-
265 is a novel, orally active, small molecule with potent inhibitory activity against all 
wild-type Raf kinases, as well as B-Raf oncogenic mutant kinases.  Like sorafenib, it 
also inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2). Raf-265 
is currently in pre-clinical evaluation, and is currently under evaluation in Phase I 
clinical trial in patients with metastatic melanoma (Khazak et al., 2007) and  
[http://clinicaltrials.gov/ct2/show/NCT00304525?term=raf-265&rank=1]. 
  Evaluation of the selectivity of Raf-targeted kinases can be complex since 
some of the efficacy of these compounds may arise from activity against non-Raf 
kinases (Khazak et al., 2007).  Therefore it still under debate if it is better to improve 
existing Raf-kinase inhibitors that will improve either their efficacy or their specificity. 
Regardless of the challenge imposed by the specificity of kinase activity inhibitors, 
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these drugs represent one class of inhibitor presently available.  Other approaches 
are also available to target protein activity by altering the expression of the target, 
rather than its activity.  One class of drugs that can target protein expression are 
includes anti-sense oligonucleotides. 
 Antisense therapy consists of the design and use of an oligonucleotide which is 
complementary to the messenger RNS (mRNA) of the gene of interest’s messenger 
RNA (mRNA). This oligonucleotide prevents expression by binding to the mRNA and 
thus inactivating it, thereby preventing its proper translation. Therefore another 
approach to inhibit Raf is by using anti-sense oligonucleotides to inhibit 
itsexpression. Some examples are the ISIS 5132 and LErafAON. ISIS 5132 is a 
phosphorothioate DNA oligonucleotide that was designed to hybridize to the 3’ 
untranslated region of c-Raf-1 mRNA (Monia et al., 1996). The success of ISIS 5132 
in its preclinical evaluation allowed the advancement of ISIS 5132 to clinical trials. 
However, the lack of patient response in phase II clinical trials caused the withdrawal 
of this compound as a therapeutic agent (Cripps et al., 2002; Oza et al., 2003). 
Different from ISIS 5132, LErafAON is liposome-entrapped derivative of a 15-mer 
antisense oligodeoxyribonucleotides, directed against the translation initiation site of 
c-Raf (Gokhale et al., 2002).  Preclinical evaluation led to the advancement of this 
compound to Phase I clinical trials and the partial response and stabilization of 
disease in some patients were enough to conclude that LErafAON is well tolerated 
at low doses.  It then underwent clinical evaluation after modification of the liposomal 
formulation (Khazak et al., 2007). Currently, inhibition through anti-sense therapy 
looks possible but still far-off, and its further evaluation in clinical trials will be 
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required to prove its efficacy as a therapeutic agent. 
 
MEK inhibitors 
 
In addition to Ras or Raf inhibitors, other drug discovery efforts have yielded 
inhibitors targeting a different element of the Ras>Raf>MEK>ERK pathway, 
including the MAPKKs, MEK1/2.  U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio]butadiene), is a potent and selective inhibitor of MEK1/2 kinase 
activity that has been used extensively in cell-based studies (Campbell et al., 2006; 
Davies et al., 2002; Duncia et al., 1998). Despite the high specificity and usefulness 
of U0126 for cell-based assays, pharmacological limitations didn’t allow it to proceed 
to clinical trials. Nowadays U0126 is widely used as a tool for examining the MEK-
ERK pathway in research laboratories (Cox and Der, 2002).    
On the other hand, there are several MEK inhibitors that have reached clinical 
evaluation. In contrast to the majority of protein kinase inhibitors which are 
competitive ATP inhibitors, MEK inhibitors are non-ATP competitive inhibitors, which 
may account for their highly selective properties (Roberts and Der, 2007). For 
example, the MEK1/2 inhibitor CI-1040 reached phase II clinical evaluation but its 
development was stopped due to insufficient efficacy (Rinehart et al., 2004). 
However, structural analysis of a CI-1040 derivative (PD0325901) in complex with 
MEK1 and MEK2 showed that inhibitor binding did not perturb ATP binding, and 
instead, bound to a novel allosteric binding pocket adjacent to the ATP binding site 
(Ohren et al., 2004). As a consequence the inhibition of the kinase activity of MEK1 
and MEK2 are likely the result of the stabilization of a catalytically-inactive 
conformation (Ohren et al., 2004). This recognition of MEK sequences that are not 
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shared with other protein kinases, and their association with an inactive 
conformation, may account for MEK inhibitor target selectivity (Roberts and Der, 
2007), thus this target selectivity may be exploited in the future for the development 
and isolation of novel MEK inhibitors. 
A second generation MEK1/2 inhibitor, AZD6244 (ARRY-142886), is an orally 
bioavailable benzimidazole derivative known to potently inhibit MEK1/2 in vitro and 
in cell-based assays (Yeh et al., 2007). The promising results from its preclinical 
evaluation at inhibiting cellular growth and inducing apoptosis, along with its efficacy 
against tumor growth in in vivo xenograft models (Yeh et al., 2007),  allowed 
AZD6244 to progress to complete its Phase I clinical trials and to advance to Phase 
II clinical evaluation (Adjei et al., 2008). 
 
Protein-protein interaction inhibitors and MCP Ras/Raf inhibitors 
 
So far I have discussed some of approaches and advances towards 
characterizing and testing inhibitors of the Ras>Raf>MEK>ERK pathway. The typical 
screening strategies have mostly been designed to identify compounds targeting the 
enzymatic activity (i.e., the kinase activity) of the target proteins. Although some of 
these inhibitors seem to have promising antitumor activity, they generally showed 
poor selectivity towards their target, most likely due to the high conservation of this 
domain among proteins (Bain et al., 2007). 
  Another way to target signaling pathways is to prevent required protein-protein 
interactions. Identifying protein-protein interaction inhibitors can be a complex 
process since it is difficult to establish the specific interface at which the inhibitor 
may be acting. Additionally, protein interaction surfaces don’t provide a highly 
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tractable binding site for drug design (Arkin and Wells, 2004). Despite these 
challenges, there are ongoing efforts to use traditional screening methods along with 
designing better strategies like using computer-generated systems to assess the 
druggability of protein-protein interactions to isolate novel protein-protein interaction 
(PPI) inhibitors (Sugaya and Ikeda, 2009). Such efforts have led to the identification 
of several PPI inhibitors of which only a few have reached clinical evaluation. A few 
examples of protein-protein interactions for which inhibitors have been isolated are: 
i) inhibitors of the cytokine Interleukin-2 (IL-2) with the α chain of IL-2 receptor (IL-
2Rα), ii) inhibitors of the family of B-cell lymphoma2 (Bcl-2)/Bcl-XL with the pro-
apoptotic molecule BAK, iii) inhibitors of the human protein double minute 2 (HDM2) 
interaction with the tumor suppressor p53, and iv) inhibitors of the ATP-dependent 
chaperone protein HSP90 with the cochaperone Hsp organization protein (HOP) 
among others (Arkin and Wells, 2004; Arkin and Whitty, 2009; Wells and 
McClendon, 2007). The identification of these PPI inhibitors represents proof of 
principle that the use of traditional methods, potentially in combination with new 
methods, will soon drive the field towards greater success at identifying PPIs. As 
more protein-protein interaction inhibitors are isolated and evaluated, the knowledge 
about this class of inhibitors and their mechanism of action will enrich the drug 
discovery field and will serve as a starting point for future drug design strategies. 
  Given the relevance of both Ras and Raf as targets for anti-cancer 
therapeutics for the onset and development of cancer, there was interest in 
developing protein-protein interaction inhibitors targeting the Ras/Raf interaction. 
Therefore, a novel family of Ras/Raf inhibitors of the MCP (Morphochem, Inc.) family 
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was identified by using a yeast two-hybrid system as a platform for a primary screen 
of small molecule compounds library to probe for inhibitors capable of disrupting the 
interaction between Ras and Raf (Kato-Stankiewicz et al., 2002; Khazak et al., 2005; 
Lu et al., 2004).   This screen was designed using C-terminally truncated H-Ras as a 
bait and full-length Raf-1 as the prey. H-Ras was favored over N-Ras or K-Ras due 
to its better expression profile in the yeast (Khazak et al., 2005).  Among the 
compounds selected by this screen were MCP1, which was further chemically 
improved to become MCP110 (Figure 1.8) (Lu et al., 2004); and a poorly active 
analog MCP122 (Kato-Stankiewicz et al., 2002).  The early characterization of these 
compounds was performed in vitro, using cell-based assays to measure the ability of 
the MCP compounds to inhibit Ras-Raf interactions and their subsequent biological 
functions (Kato-Stankiewicz et al., 2002). This study revealed the ability of MCP 
compounds to inhibit Ras-mediated cell proliferation, anchorage-independent growth 
and downstream effectors of Ras signaling in cell-based systems and xenografts 
(Campbell et al., 2007; Kato-Stankiewicz et al., 2002; Skobeleva et al., 2007).  
However, the mechanism of action of these putative Ras/Raf interaction inhibitors is 
not well understood. More recent evidence also indicates that MCP compounds 
have activity towards melanoma cell lines in which B-Raf is mutated (Hao et al., 
2007), thereby bringing into question their specific site of action.  
Characterizing the mechanism of action of protein-protein interaction inhibitors is 
a challenging task.  In this dissertation we present the nematode Caenorhabditis 
elegans vulva development as tractable genetic model for the evaluation of MCP 
activity in vivo, in combination with biochemical assays and cell-based assays, with 
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the goal to further understand the mechanism of action of MCP compounds as is 
described further in Chapter III of this dissertation. 
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Figure 1.8 Chemical structure of MCP110 (Khazak et al., 2007) This polar 
compound is well-suited to interact with the flat interfaces of membrane-bound Ras 
and Raf. 
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C. elegans as a model for drug discovery 
 
 
Caenorhabditis elegans was originally described as a powerful research model 
by Sydney Brenner (Brenner, 1974). As a model system, this nematode offers many 
advantages such as transparent internal structures that are easily detected using a 
dissecting microscope, a short life cycle of 3 days that allows for rapid phenotypic 
analysis and simple maintenance of laboratory strains. C. elegans reproduces 
asexually, and hermaphrodites can produce approximately 300 progeny in one life 
cycle, resulting in robust sample sizes for the design of high throughput studies. To 
date, there has been extensive research and characterization of C. elegans at the 
molecular, developmental and behavioral level. Given this extensive 
characterization, C. elegans is now often used to study a large variety of biological 
processes including apoptosis, cell signaling, cell cycle, cell polarity, gene 
regulation, metabolism, aging and sex determination (Kaletta and Hengartner, 
2006). 
In terms of pharmacological studies, C. elegans possesses many advantages as 
a model organism.  For example, it is easy to design simple dosing schemes and 
drug studies in the context of a whole organism.  In addition, because the worm is 
transparent, fluorescent probes can be engineered to easily monitor protein 
expression in living animals.  Because of the worm’s small size (1mm), most assays 
can be carried out in microtiter plates either on agar or in liquid using more than one 
hundred animals in a single well of a 96-well plate (Kaletta and Hengartner, 2006). 
Most importantly, C. elegans possesses signaling processes that are evolutionarily 
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conserved among species, which allows the opportunity to exploit this model 
organism for the better understanding of complex signaling pathways in mammals. 
Another potential advantage of C. elegans versus in vitro or cellular models is 
that instead of using a target of interest in an isolated system it can be instead 
studied in the context of a whole organism. (Kaletta and Hengartner, 2006). 
Performing whole organism studies adds perspective in understanding the 
bioavailability of the compound, although it can be problematic if the particular 
compound of interest is poorly penetrant through the worm cuticle. 
In addition to the high degree of conservation of proteins and signaling pathways 
whose functions are well understood, the existence of fewer orthologs also simplifies 
the study of single pathways in the worm. For example, in mammals there are three 
Ras homologs (H-, K- and N-Ras), whose varied activation mechanisms and activity 
in cell-dependent contexts add significant complexity to the interpretation of 
experimental results. In contrast, the worm possesses only one functional Ras 
ortholog (LET-60), which simplifies the characterization and function of this protein in 
the worm. Moreover, it also simplifies the study of Ras-induced signaling for genetic 
or pharmacological studies (Hara and Han, 1995; Reiner et al., 2008), as will be 
further discussed in Chapters II and III of this dissertation. It is also relevant to 
mention that C. elegans phenotypes are not expected to correlate with human 
pathology but this is not required in order to obtain relevant pathway information; in 
other words, one can study pathways relevant for human cancer although worms do 
not get cancer.  However, even existing mammalian models are often not reliably 
predictive of drug action in humans; thus the use of non-mammalian models early in 
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the process are cost-effective and should deliver fast answers to a discovery 
problem (Kaletta and Hengartner, 2006). 
One critical aspect of the drug discovery process is early analysis of 
bioavailability, related toxicity and potential off-target effects. These are compound 
qualities that are poorly assessed in mammalian cell-based assays and often are not 
detected until lead compounds are being evaluated at the very late preclinical stage 
and unfortunately often not even until evaluating expensive clinical trials are 
undertaken.  For this reason, another advantage offered by the use of the worm for 
drug discovery is that if specific drug effects are detected, it means that the drug is 
bioavailable, the drug has reached the target tissue and most likely has been able to 
target the protein activity, which are necessary features of whole-animal 
pharmacology in mammals (Kaletta and Hengartner, 2006).  
So far I have discussed the general advantages of using C. elegans as a model 
for drug discovery; however I have yet to discuss one of the major advantages of 
using this system, which is the power to combine genetic screens with 
pharmacology. For many years C. elegans has been used for genetic high 
throughput screens as the standard to uncover gene function. The idea of using a 
similar platform, but for high throughput drug screens with C. elegans seems like a 
workable idea. The key elements are to develop an assay using a specific readout 
that would be sensitive and selective to the action of small molecules targeting the 
protein of interest. For this purpose, the target of interest should be conserved in the 
worm and its function should be well understood. Based on the previous information, 
transgenic worm strains with sensitized genetic backgrounds could be easily 
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generated to create a robust readout that would fit the purpose of a HTS.  The 
success of a screen of this nature relies in the selection of a proper readout and also 
in the composition (type of chemical entities) of the compound library being 
screened. An example of the validation and future prospects for a drug screen using 
C. elegans, will be discussed in the fourth chapter of this dissertation, where a novel 
platform was generated and validated for the screen of novel Rac or Rac pathway 
inhibitors. 
 In classical or forward genetic screens, the genome of an organism is randomly 
mutagenized to generate large numbers of mutants, which are screened for a 
desirable phenotype or trait, such as alteration in growth, appearance or behavior. 
Mutants with the desired phenotype are collected and used to identify and 
characterize genes involved in the process of interest (Jones et al., 2005; Kaletta 
and Hengartner, 2006; Zheng and Chan, 2002).  This classical genetic screen 
method can be modified to suit pharmacology studies. The resulting approach is 
termed chemical genetics. This approach takes advantage of the traditional “forward 
genetics approach” to screen for mutants that are resistant or hypersensitive to the 
effect of a small molecule compound, resulting from mutations that alter the key 
target or a pathway-related element (Jones et al., 2005; Kaletta and Hengartner, 
2006) (Alaoui-Ismaili et al., 2002).   With this type of screen the worm becomes 
useful for the identification of the target of compounds of interest. An example of the 
success of this approach was reported in Ranhanathan et al, where worms 
harboring loss-of-function mutations in the C. elegans serotonin reuptake transporter 
(SERT) MOD-5 were resistant to the action of the serotonin reuptake inhibitor 
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fluoxetine, as shown by changes in specific behavior patterns, identifying MOD-5 as 
a candidate target of fluoxetine. These in vivo studies contributed to increase our 
knowledge about the mechanism of action of fluoxetine and also offered the 
opportunity to find novel targets by further characterization in the worm model 
(Ranganathan et al., 2001). 
 So far I have discussed that the worm can provide information that can be 
beneficial for further characterization and understanding of the molecular targets of a 
given compound. Besides the expected results in a drug screen, the use of C. 
elegans could also reveal unexpected off-target effects by displaying changes in 
behavior, phenotype or defects in development.  Given the excellent characterization 
of C. elegans in various biological aspects, it would be possible to revisit databases 
or the literature to establish new correlations between the off-target effect and a 
particular gene.  In work published by Lackner et al., C. elegans was presented as a 
valuable model to genetically identify the target of unusual pro-apoptotic FTIs and 
thereby unveil their true mechanism of action (MOA) (Lackner et al., 2005). During 
the development of a next generation FTI, BMS-214662, at Bristol-Myers Squibb, it 
was observed that this FTI possessed proapoptotic activity that did not correlate with 
the mutational status of Ras or the activity against farnesyl transferase or 
geranylgeranyl transferases (Rose et al., 2001). As a consequence, activity of this 
BMS-214662, was thought to be the result of off-target activity.  Given the lack of 
positive results in mammalian cells and the well-characterized apoptosis 
mechanisms in the worm, C. elegans was then chosen to as the model of choice to 
further characterize of this compound. First it was found that BMS-214662 also had 
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pro-apoptotic activity in the worm, thus adding evidence that the real target of these 
inhibitors may be also conserved across species. The use of forward genetic 
screens and RNAi analysis then identified candidate genes that phenocopied the 
effects of the pro-apoptotic FTIs.  Among these genes were proteins involved in 
vesicular trafficking and the prenyltransferase RabGGTII, which is responsible for 
the geranylgeranylation of the Rab family of small GTPases (Figure  1.1) (Lackner et 
al., 2005). Further genetic analysis in C. elegans identified RabGGTII as the target 
responsible for FTI-driven apoptosis in worms and further testing confirmed the 
target in mammalian cells. This study provided evidence supporting the worm as a 
powerful genetic tool for the in vivo characterization of pharmacological inhibitors 
(Lackner et al., 2005).  
 Led by these examples, there is now strong evidence that supports C. elegans 
as an alternative model for pharmacology studies.  It is noteworthy that C. elegans 
does not replace mammalian cell culture models or other higher animal models; 
nevertheless, it provides the advantage of a living organism due to its simplicity and 
well-characterized development and behavior.  The extensive characterization of this 
model also increases the chances to uncover potential off-target effects earlier in the 
drug discovery process, which can reveal critical information in the activity of the 
drug and the potential existence of additional targets. Like on-target effects, any off-
target effects observed in the worms may not translate directly into humans in terms 
of phenotypic endpoints, but can still provide valuable clues to the pathway or 
protein being targeted.   
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In summary, there is considerable information derived largely from proof-of 
principle experiments showing the potential of C. elegans as a model for drug 
discovery. More importantly a successful platform would need to be selected along 
with the appropriate readout to develop and validate the corresponding assay. C. 
elegans, like any other preclinical model, has its advantages and disadvantages, but 
the availability of tools for its study, the ease with which new transgenic animals are 
created, the low cost of maintenance plus the valuable databases available for the 
better understanding of the model, have collectively made C. elegans a highly useful 
model for drug discovery. In work presented in this dissertation, I have used C. 
elegans to characterize the actions of small molecule MCP compounds targeting the 
Ras-Raf interaction.  
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Abstract 
 
 The human RAS genes constitute the most frequently mutated oncogenes in 
human cancers, and the critical role of aberrant Ras protein function in oncogenesis 
is well established. Consequently, considerable effort has been devoted to the 
development of anti-Ras inhibitors for cancer treatment. An important facet of 
molecularly targeted cancer drug discovery is the validation of a target-based 
mechanism of action, as well as the identification of potential off-target effects. This 
chapter describes the use of the nematode worm Caenorhabditis elegans for simple, 
inexpensive pharmacogenetic analysis of candidate molecularly targeted inhibitors 
of mutationally activated Ras, with a focus on the Ras>Raf>MEK>ERK mitogen-
activated protein kinase pathway. This protein kinase cascade is well conserved 
from worms to humans and is well established as a critical player in the signaling 
events leading to vulval formation in C. elegans. Excess activity results in the 
development of a multivulva (Muv) phenotype, whose inhibition by test compounds 
can be characterized genetically as to the specific step of the pathway that is 
blocked. In addition, off-target activities can also be identified and characterized 
further using different strains of mutant worms. This chapter presents proof-of-
principle analyses using the well-characterized MEK inhibitor U0126 to block the 
Muv phenotype caused by the constitutively activated Ras homolog C. elegans LET-
60. It also provides a detailed description of protocols and reagents that will enable 
researchers to analyze on- and off-target effects of other candidate anti-Ras 
inhibitors using this system.  
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Introduction 
The nematode worm Caenorhabditis elegans is an organism commonly used by 
researchers wishing to model human biology. The simple lifestyle and body plan of 
C. elegans allow many facets of its development and behavior to be perturbed 
genetically (Brenner, 1974).  Coupled with the extensive evolutionary and functional 
conservation of signaling proteins, the tractable genetics of C. elegans allow the 
creation of many valuable genetic tools for manipulating signaling pathways.  These 
tools can be isolated in screens or created transgenically, and the resulting 
phenotypes can be assayed relatively easily. Perhaps the best studied of such 
pathways in C. elegans is the epidermal growth factor receptor (EGFR) receptor 
tyrosine kinase pathway that activates Ras, which subsequently activates the 
Raf>MEK>ERK mitogen-activated protein kinase (MAPK) cascade (Figure. 2.1). 
This EGFR-stimulated Ras pathway is very well conserved in evolution, with all 
components found in C. elegans and Drosophila as well as in all vertebrate species.  
In C. elegans, this pathway controls the development of the vulva, an epithelial 
aperture through which fertilized eggs are laid. 
 Mutations perturbing vulval development are easy to identify (Figure. 2.2).  
Defective vulval induction results in a Vulvaless (Vul) phenotype, and embryos hatch 
inside the animal.  Excessive vulval induction results in the development of 
nonfunctional ectopic pseudovulvae, resulting in the Multivulva (Muv) phenotype. 
The molecular pathways that regulate these developmental events are highly 
conserved amongst all metazoans (Moghal and Sternberg, 2003). By screening for 
these phenotypes and modifiers of these phenotypes, mutations in over 50 genes 
that govern vulval development have been identified.  These studies have 
   47 
demonstrated that the worm LET-23>LET-60>LIN-45>MEK-2>MPK-1 MAPK 
cascade, which is highly conserved with the homologous 
EGFR>Ras>Raf>MEK>ERK MAPK pathway in mammals, is a critical signaling 
pathway that governs cell fate decisions needed for proper vulval formation.  
 Studies in model systems like C. elegans and Drosophila have been 
instrumental in identifying previously unknown components of these pathways, or 
determining the functional role of known pathway components.  For example, the 
human Raf scaffolding protein Ksr was originally identified in mutant screens in C. 
elegans and Drosophila (Kornfeld et al., 1995; Sundaram and Han, 1995; Therrien et 
al., 1995), and the functional relationship of the SEM-5/Grb2 adaptor protein to other 
pathway components was originally determined in C. elegans (Clark et al., 1992). 
Thus, regulation of vulval cell fate in C. elegans is a useful differential biological 
readout of EGFR>Ras>Raf>MEK>ERK pathway activity, such as the R7 
photoreceptor in the Drosophila eye or like cell proliferation in human epithelia.  
Because the signaling module itself, from the EGFR ligands (e.g., EGF) to the 
Ets-like transcription factors, is highly conserved and similarly regulated in both 
worms and humans, it is likely to have the same pharmacological targets and be 
modified by the same pharmacological treatments in both worms and humans. For  
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Figure 2.1.    A conserved Ras>Raf>ERK MAPK pathway specifies growth in 
mammalian cells and vulval cell fate in C. elegans. In the worm, an EGFR-ligand-
like signal, LIN-3 (released from the anchor cell in the gonad; see Fig. 30.2), binds to 
the LET- 23 receptor tyrosine kinase, which becomes activated and binds the 
adaptor/exchange factor complex SEM-5/SOS-1 (Grb- 2/SOS) to activate the Ras 
small GTPase LET- 60.  Activated Ras then triggers the equivalent of the 
Raf>MEK>ERK MAPK cascade of kinases. ERK/MPK-1 enters the nucleus to 
phosphorylate and activate or inactivate, respectively, Ets family transcription factors 
such as LIN-1, which negatively regulates the induction of vulval precursor cells. 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example, many human small GTPases, such as the LET-60 orthologs K-Ras, H-Ras 
and N-Ras, require post-translational modification by farnesylation at their C-termini 
to target the proteins to membranes and to promote correct biological activity.  First 
generation FTase inhibitors (FTIs) manumycin and gliotoxin were capable of 
blocking excessive LET-60 signaling in worm vulval induction (Clark et al., 1995),  
although subsequent studies found these and other FTIs to be ineffective against the 
Ras isoforms most commonly mutated in human cancers (Rowinsky, 2006).   
In addition, the degree of functional conservation of C. elegans pathways is such 
that off-target drug effects can also be conserved across species and identified in C. 
elegans. When a newer generation FTI, BMS-214662, was unexpectedly found to 
have off-target pro-apoptotic activity (Rose et al., 2001), many attempts to identify 
the mechanism for this property failed in mammalian cells.  However, the pro-
apoptotic function was conserved in C. elegans. Genetic screens then identified 
genes whose loss of function caused the same phenotype as the p53-independent, 
caspase-dependent germline apoptosis induced by a panel of pro-apoptotic FTIs 
(Lackner et al., 2005). These genes control endosome-lysosome and 
autophagosome-lysosome docking and fusion, and the conserved Rab prenylation 
enzyme, Rab geranylgeranyltransferase (RabGGTase/GGTase II), was shown to be 
the key FTI target responsible for induction of apoptosis.  Target identification was 
then confirmed in mammalian cells.  This study illustrates the utility of using C. 
elegans to identify novel pharmacological targets of known drugs. Several 
conserved pharmacological targets in the nervous system have been identified in C. 
elegans. For example, in C. elegans nicotinic acetylcholine agonists activate 
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acetylcholine receptors (Lewis et al., 1980) and GABA-A receptor agonists activate 
GABA-A receptors (McIntire et al., 1993). Furthermore, tricyclic (Horvitz et al., 1982) 
and SSRI (Weinshenker et al., 1995) antidepressants promote serotonin signaling, 
and putative molecular targets of off-target effects of fluoxetine were identified using 
C. elegans genetics (Choy et al., 1999).  Together, these observations suggest that 
C. elegans is an excellent system for studying both intended and off-target effects of 
pharmacological agents. 
Because of the potential for detailed genetic manipulation of conserved 
pathways, the use of C. elegans allows the researcher to determine at which level in 
the pathway a drug acts in vivo. For example, the mutant allele let-60(n1046gf) 
introduces a gain-of-function (gf) G13E mutation into the worm Ras protein, LET-60, 
thereby inactivating its intrinsic and GAP-stimulated GTP hydrolysis activity and 
trapping the protein in its active GTP-bound form. Hyperinduction of vulval tissues 
causes a Muv phenotype that is easily scored by counting the ectopic ventral tissue 
protrusions on the normally smooth surface of the animal (Figure. 2.2). The strong 
Muv phenotype caused by let-60(n1046gf) can be suppressed genetically or 
pharmacologically by compromising pathway function either at or downstream of let-
60, whereas perturbation of upstream pathway function has little effect (Beitel et al., 
1990). Similar types of manipulation can be performed at most levels of the pathway, 
either by use of isolated strains with in situ mutations or by generation of transgenic 
strains in which the pathway is manipulated in trans.  In Table I we have listed 
activated pathway reagents that cause a Muv phenotype. 
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Lacking this extensive genetic toolkit for analyzing EGFR>Ras>Raf>MEK>ERK 
MAPK signaling, other model systems have their own advantages and 
disadvantages. Human cell culture can be readily manipulated genetically, and has 
the advantage of excellent biochemical readouts, but it is an ex vivo system, and 
many cancer cell lines have extensive genetic abnormalities that are distinct from 
those found in the original tumors. Mice have the advantage of being an in vivo and 
mammalian system, but they are expensive, lack the reagents capable of altering 
each pathway component, and extensive manipulation of this pathway would result 
in lethality; further, despite their widespread use in preclinical anti-tumor efficacy 
studies, they are surprisingly nonpredictive of anti-tumor and off-target normal cell 
toxicity in the cancer patient (Sharpless and Depinho, 2006).  Zebrafish are relatively 
inexpensive and have the benefit of complex organ systems, but they are also 
subject to some of the caveats of the mouse system. For our purposes, although no 
system is perfect, C. elegans is particularly useful because these animals are 
inexpensive, the genetic tools are currently available and simple to work with, and 
one can rapidly assay different inhibitors. 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Figure 2.2. Normal or aberrant vulval formation in C. elegans is determined by 
the exposure of vulval precursor cells to graded levels of activation of the 
Ras>Raf> MEK>ERK MAPK signaling pathway. Under ‘‘normal signaling’’ 
conditions (top worm photograph), the anchor cell (AC) of the gonad releases 
signals (e.g., LIN-3 ligand) to activate the Ras pathway in adjacent VPCs (P6.p, 
P7.p, etc.). In wild-type animals, VPCs adjacent to the AC receive the strongest 
signal. These cells assume 1° and 2° fates and together develop into a functional 
vulva.  The more distal VPCs are normally exposed to lower levels of signaling 
inputs from the Ras pathway. These cells remain uninduced and therefore assume a 
3° fate and fuse to the hypodermal syncytium rather than contributing to vulval 
formation. Under conditions of ‘‘pathway inhibition’’ (middle worm photograph), 
whether because of loss -of-function mutations or drug treatments, blockade of 
critical elements of the pathway leads to the absence of inductive signals. All VPCs 
therefore remain undifferentiated and assume a 3 cell fate that results in a failure to 
develop a functional vulva (vulvaless phenotype) and hence the inability to lay eggs. 
As a consequence, the mature eggs hatch inside the parent, causing the ‘‘bag-of-
worms’’ phenotype shown. Conversely, constitutive signaling (‘‘activating mutations,’’ 
bottom worm photograph) leads to hyperinduction of all VPCs, which adopt only 1 
and 2 fates, resulting in the formation of both a single functional vulva and additional 
protruding nonfunctional vulva-like structures called pseudovulvae. Worms with such 
pseudovulvae are described as exhibiting a multivulva (Muv) phenotype. 
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2. Experimental protocol 
The experimental protocol described in this section has been developed to 
study both on-target and off-target effects of pharmacological inhibitors of Ras 
function in the EGFR>Ras>Raf>MEK>ERK MAPK pathway, in which inhibition of the 
Muv phenotype serves as a readout for inhibitor activity. The following section 
illustrates the use of this protocol by describing a proof-of-principle experiment to 
inhibit the pathway downstream of Ras.  We used the well-characterized MEK 
inhibitor U0126 (Duncia et al., 1998) to block the Muv phenotype induced by the 
constitutively activated worm Ras homolog, LET-60. This protocol can be adapted to 
analyze other pharmacologic inhibitors and other signaling pathways. 
 
2.1.  Overview of experimental procedure 
As shown in the schematic overview (Figure. 3), each experiment involves 
pouring the fresh agar plates on which the experiment will be performed, adding 
inhibitor or vehicle to the agar, growing a lawn of bacteria on the agar to provide 
food for the worms, growing the worms in the presence or absence of the inhibitor, 
and finally scoring the phenotype of the worms under each condition.  Each 
experiment therefore generally takes 5 to 8 days to complete, depending on the 
developmental stage to be scored and on any growth delay induced by the inhibitors 
tested. For consistency and accuracy, it is critical to follow the recommended time 
course every time an experiment is run.   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Figure 2.3. Schematic overview and time line for a typical experiment testing 
inhibitors of the Muv phenotype in robust or sickly animals. Details are 
provided in the text. 
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2.2 Preparation of materials and reagents 
Instructions were adapted from the following sources: 
• Alkaline buffer and bleaching for synchronized L1 larvae (Bianchi and Driscoll, 
2006) 
• NGM agar, M9 buffer, OP50 strain of E. coli (Brenner, 1974) 
• Mounting worms on agar pads and DIC microscopy (Shaham, 2006) 
• General C. elegans culturing techniques (Stiernagle, 2006)  
2.2.1  2% Neutral Growth Medium (NGM) agar (1 liter)  
o 20 g Bacto agar    
o 3 g NaCl     
o 2.5 g Bacto peptone    
o 1 ml of 5 mg/ml (dissolved in 100% ethanol) cholesterol     
o 975 ml dH2O  
Autoclave for 60 minutes.   When cooled to approximately 50˚C, add sterile: 
o 1 ml of 1M MgSO4 
o 1 ml of 1 M CaCl2  
o  25 ml of 1 M KPO4, pH6.0*  
*To make 1 M KPO4, pH 6.0, first prepare and autoclave solutions of 1 M KH2PO4 
(monobasic) and 1 M K2HPO4 (dibasic).  Adjust the KH2PO4 pH to 6.0 by gradually 
adding 1 M K2HPO4. 
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This agar is used to pour plates.  Make only enough 2% NGM agar for use in 
pouring plates that day.  If excess agar remains after pouring plates for the inhibitor 
experiment, it can be used to pour stock plates to maintain worm strains.  Store the 
other solutions (salts, buffers) at room temperature in 250-ml glass bottles, each 
containing 100 ml.  
 
2.2.2  3% NGM agar (1 liter) 
This agar is used for mounting worms for microscopy.   To prepare the 3% NGM 
agar, follow the same recipe as for 2% agar above, but increase the Bacto agar to 
30 g per liter.  Aliquot 2 to 3 ml into sterile disposable glass tubes. Seal the opening 
of each tube with Parafilm and store at room temperature until needed. Each aliquot 
is sufficient to make enough agar pads to mount 10-15 slides (see later), so it is 
probably unnecessary to make more than 250 ml of 3% NGM agar at any given 
time. 
 
2.2.3  1X M9 buffer (minimal salts) (1L) 
o 5.8 g Na2HPO4    
o 3.0 g KH2PO4    
o 0.5 g NaCl     
o 1.0 g NH4Cl     
o Add dH2O to adjust the final volume to 1 liter and autoclave (no longer 
than 30 m) before use. 
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Sterile 1X M9 buffer is commonly used for the handling of worms in many different 
protocols. Here it is used to dilute the test drugs and to wash the worms after the 
bleaching protocol. 
 
2.2.4  Inhibitor / drug dilutions 
Inhibitors are generally made up and stored as stock solutions of 10, 20 or 50 
mM in dimethyl sulfoxide (DMSO) or ethanol solvent, and each of these solvents can 
be used as vehicle-only controls as appropriate.   All working dilutions of stock 
solutions of inhibitors (whether containing control or test inhibitor, or vehicle only) 
should be prepared at the time of use in sterile 1X M9 buffer, which is compatible 
with worm development and can be distributed evenly in the agar plates.  Working 
dilutions of each inhibitor should be planned such that the desired final concentration 
can be achieved by distributing 150 µl of inhibitor over 5 ml of agar.  The rationale 
for choosing a range of working concentrations is described below in the proof-of-
principle experiment.  It is important to note that the sensitivity of different worm 
strains to a given inhibitor may vary considerably for reasons that may or may not be 
related to the gene of interest for the pathway being tested.  Therefore each strain 
must be subjected to control dose-finding experiments and not assumed to be 
equally sensitive to the same inhibitor dose as another strain.  Furthermore, a 
consistent method for obtaining progeny (synchronous egg-laying versus bleaching 
parental worms) should be used for each strain, since the method may alter the 
results of some experiments.   
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2.2.5  Alkaline buffer / bleaching solution (5 ml) 
o  1.25 ml 1M NaOH 
o  1 ml commercial hypochlorite bleach 
o  2.75 ml ddH2O  
2.2.6 Worm strains 
Table I lists the properties of various worm strains suitable for evaluating Ras 
function, particularly with respect to the EGFR>Ras>Raf>MEK>ERK MAPK 
pathway. We note that independent strains containing in situ mutations or 
transgenes are not necessarily otherwise genetically uniform, so appropriate 
controls should be performed for each strain.  For each strain, it is also particularly 
important to note the basal distribution of worms expected to display the Muv 
phenotype.   
Standard worm husbandry steps are taken to maintain stock worm strains.  
For each generation, two or three adult worms are transferred to standard 60-mm 
dishes containing 12 ml 2% NGM agar and spotted with approximately 250 µl OP50 
bacteria (see later). It is also important to pursue best practices to avoid genetic drift 
of strains.  Strains with a growth disadvantage are particularly prone to acquiring 
modifiers.  C. elegans strains survive two to three months on their NGM plates if 
Parafilmed after starvation. All strains should be kept as Parafilmed stocks, and 
active cultures can be renewed as necessary from the Parafilmed plates. C. elegans 
strains can also be frozen, and active cultures should be periodically renewed from 
frozen reserves (Stiernagle, 2006). 
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3.  Experimental procedure 
 Investigators new to C. elegans are highly recommended to also consult the 
references cited in Bianchi and Driscoll (2006), Shaham (2006), Stiernagle (2006) 
for excellent visual aids and basic worm handling tips. 
 
3.1 Neutral growth medium  agar plate preparation 
NGM agar plates must be prepared fresh for each experiment, since they 
tend to dehydrate over time, which affects the final drug concentration.  Therefore, 
pouring fresh plates for each experiment ensures consistent volume and drug 
concentration and decreases inter-experiment variability. To further improve 
consistency and minimize dehydration, we recommend the use of six-well tissue 
culture plates, in which each well is the equivalent of a single 35 mm tissue culture 
dish, and filling the wells about half full with agar.  On Day One, prepare and pour 
NGM agar (5 ml per well) into only the four outer wells of the 6-well tissue culture 
plates, leaving the two center wells empty. This approach further avoids variability 
due to uneven dehydration across the plates, and ensures that all wells will continue 
to contain an equal volume of agar throughout a given experiment. Freshly poured 
plates should be stored in a tightly covered container at room temperature; plastic 
food storage containers do nicely.  To improve the even dissemination of inhibitors 
into the agar, wait approximately 24 h before the next step. 
Table I.  Mutant strains of C. elegans available for characterization of Ras/ERK MAPK signaling pathway inhibitors 
 
  
 
Worm 
 gene 
 
Ref. 
 
Mammalian  
homolog 
 
Type of 
mutation* 
 
Allele 
 
Strain‡ 
 
Basal Muv 
§ % 
 
Notes 
 
lin-3  
 
 Hill and 
Sternberg (1992) 
 
EGF 
 
Transgenic 
over-
expression 
 
syIs1 
 
PS112
3 
 
90 
 
Integrated transgene containing 
wild-type lin-3 genomic DNA. 
Confers a dominant multivulva 
(Muv) phenotype. 
 
 
lin-15  
 
Ferguson and 
Horvitz 
(1985); Huang 
et al.,(1994)  
 
None 
known 
 
lf 
 
n765 
 
MT 
8189 
 
77 
 
 
Temperature sensitive mutant: 
animals are Muv at 25°C, wild 
type at 15˚C.  LIN-3/EGF 
ectopically expressed in mutant. 
 
 
let-23  
 
Katz et al., 1996) 
 
EGFR 
 
 
gf 
(C359Y) 
 
sa62 
 
PS152
4 
 
89 
 
Activating mutation in the 
extracellular domain of the LET-
23 receptor; Muv phenotype is 
ligand-independent. 
 
 
let-23 
 
 
Moghal and 
Sternberg (2003) 
 
 
EGFR 
 
gf 
(C359Y, 
G270E) 
 
 
sa62, sy621 
 
PS 
4064† 
 
100 
 
Double extracellular domain 
mutations confer a stronger ligand-
independent Muv phenotype. 
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Worm 
 gene 
 
Ref. 
 
Mammalian  
homolog 
 
Type of 
mutation* 
 
Allele 
 
Strain
‡ 
 
Basal Muv 
§ % 
 
Notes 
 
sos-1  
 
 
Modzelewska et 
al., (2007)  
 
Sos 
 
gf 
(G322R) 
 
sy262, let-
23(sy1) 
 
ND91
†† 
 
68 
 
Muv phenotype due to sy262 is 
visible only in the sensitized let-
23(sy1) background. 
 
let-60  
 
Ferguson and 
Horvitz  (1985)  
 
Ras 
 
gf 
(G13E) 
 
 
n1046 
 
 
MT 
2124 
 
57-90§§  
 
 
Mutation predicted to disrupt 
intrinsic GTPase activity, resulting 
in constitutive activation (similar 
to G12V but predicted to be 
weaker). 
 
lin-45 
(AA)  
 
Chong et al., 
(2001); 
Rocheleau et 
al., (2001) 
 
Raf 
 
TG overexp. 
gf (S312A, 
S435A) 
 
 
kuIs57 
 
 
MH 
2209 
  
 
91 
 
Integrated transgene driving full-
length lin-45(AA) with mutational 
loss of the Akt negative regulatory 
phosphorylation serines.  
 
lin-45 
(TM) 
 
 
Sieburth et al., 
(1998); Dickson 
et al., (1992) 
 
Raf 
 
Conditional 
TG 
overexp. gf 
 
kuIs17 
 
 
UP11
54 
 
13 
 
Integrated transgene in which 
hsp16-41 heat-shock promoter 
drives expression of Drosophila 
Raf kinase domain (411 C-
terminal amino acids) fused to the 
Torso transmembrane domain. 
Activation is independent of Ras. 
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Worm 
 gene 
 
Ref. 
 
Mammalian  
homolog 
 
Type of 
mutation* 
 
Allele 
 
Strain‡ 
 
Basal 
Muv § % 
 
Notes 
 
lin-45 
(ED)  
 
(Chong et al., 
(2001); 
Rocheleau et 
al.,(2005) 
 
Raf 
 
 
Conditional 
TG overexp. 
gf (T626E, 
S629D) 
 
 
csEx72 
 
UP1226  
 
37 
 
Non-integrated transgene (unstable) 
with hsp16-41 heat-shock promoter 
driving lin-45(ED) containing T626E, 
S629D phosphomimetic activating 
mutations.  
 
mek-2 + 
mpk-1  
 
 
Lackner and 
Kim (1998)  
 
MEK/ 
ERK 
 
Conditional 
overexp. gf 
 
gaIs36 
or 
gaIs37 
 
SD418 
or 
SD470 
 
Not avail. 
 
Integrated transgene with both 
Drosophila MEK [Dsor1 gf 
mutation] and C. elegans ERK [mpk-
1 gf mutation (D324N)].  Both 
constructs are driven by the hsp16-41 
heat-shock promoter. Muv phenotype 
is observed only when animals are 
grown at 25°C, but not at 15-20°C. 
 
 
lin-1  
 
 
 
Beitel et al., 
(1995)  
 
 
Ets-related 
transcription 
factor 
 
 
 
lf 
 
 
sy254 
 
 
MT 
7567 
 
 
90-100 
 
 
Loss of function of lin-1 confers Muv 
phenotype. 
62 
 * overexp, overexpression; gf, gain of function; lf, loss of function. 
‡ Most strain names were identified using the public domain C. elegans database Wormbase (http://www.wormbase.org/). This 
database also provides basic information on each strain, as well as links to literature in which the strain of interest has been cited.  Not 
all the mutant strains mentioned here were publicly available at the time of preparation of this document. We obtained marked strain 
numbers from the original laboratory sources as follows:  † Paul W. Sternberg, †† Nadeem Moghal,  Stuart K. Kim.  
§ The penetrance of the multivulva (Muv) phenotype among mutant strains of the Ras/ERK MAPK pathway varies. This variation may 
be due to the type of genetic lesion and/or to the role of the mutated gene in Ras/ERK MAPK signaling that regulates worm vulval 
development.  
§§For this strain, we routinely observe 85-90% Muv worms when they are grown from fresh cultures.   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Basal Muv 
§ % 
 
Notes 
 
lin-31  
 
 
 
Hill and 
Sternberg 
(1992); Miller 
et al., (1993); 
Tan et al., 
(1998)  
 
Winged 
helix  
transcription 
factors 
 
gf 
 
 
n301 
 
MT30
1 
 
~70 
Identified in a general screen for 
Muv or Vul enhancement.  Loss of 
function of lin-31 confers Muv 
phenotype. Healthier than lin-
1(sy254). 
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3.2 Inhibitor addition to agar plates 
Add inhibitor 24 h after pouring the agar (i.e., on day 2). Each plate is 
generally devoted to a single concentration of a given inhibitor, with one well 
containing the DMSO or ethanol vehicle control and the three remaining wells 
containing inhibitor, all at the same concentration in order to generate triplicate data 
points.  Each inhibitor concentration should be tested in its own plate.  It is strongly 
recommended to use the same layout for all plates in the experiment, both for 
consistency and to decrease the chances of error.  Add 150 µl of the working dilution 
of inhibitor or vehicle, freshly prepared in sterile 1X M9 buffer as indicated in earlier, 
drop wise to the agar surface of the appropriate well.  Immediately swirl and then 
rock the plate in perpendicular directions to ensure uniform drug distribution.  Apply 
the drug at a sufficient concentration that will result in the desired final concentration, 
once the drug has been absorbed into the entire 5 ml volume of agar.  Return the 
plates to their container and allow the inhibitors to absorb into the agar for 24 h. 
 
3.3  Seeding NGM plates with bacterial food for the worms 
It is best to use OP50, a laboratory strain of E. coli, to feed the worms for 
these experiments (Brenner, 1974; Stiernagle, 2006). Grow OP50 to stationary 
phase in LB medium without antibiotics.  It is not necessary to use fresh OP50 
cultures, but the same culture should be used for all experimental plates.  On Day 
Three, spot E. coli OP50 bacteria onto the plate to provide food for the worms by 
adding 80 µl of bacteria to the center of each well.  Swirl to distribute.  This lawn of 
OP50 will be sufficient to feed the animals for the duration of the experiment. Store 
plates as before, in tightly covered containers at room temperature. 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3.4  Adding animals to the bacterial lawn 
Add animals to the plates 24 h after spotting the bacteria.  On Day Four, 
begin either the egg-laying assay or the bleaching for hatch-off protocol as described 
later.  Healthy strains grown at 20˚C will form L4 larvae between 48 and 60 h post-
egg laying or bleaching, and adults thereafter (Brenner, 1974).  The timing for sickly, 
slower growing strains will need to be adjusted accordingly.  
3.5  Egg-laying assay to obtain semi-synchronized populations 
In one generation, the worms from a single stock 60-mm dish will grow to 
produce sufficient progeny to test one experimental condition, that is, 4 wells of a 6-
well plate.  To start the egg-laying assay, transfer 12 to 15 adult hermaphrodite 
worms to each well.  More parents can be added for less fecund strains.  Place the 
plates in a sealed plastic container at 20˚C (or a viable temperature appropriate for 
the strain).  Allow them to lay eggs for 3 h.  Then, remove all the parents and return 
plates to the incubator until the progeny hatch and reach the desired developmental 
stage.  This can be as long as 4 days (e.g., for lin-1(null) worms that will be scored 
as L4 larvae) or as short as 60 h (e.g., let-60(gf) worms that will be scored as 
adults). It is not necessary to begin with exactly the same number of adult animals in 
each well because the eventual worm progeny will be scored according to the 
percentages of all the resulting worms that display a given phenotype, not according 
to absolute numbers. 
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3.6  Bleaching worms for hatch-off to obtain a synchronized population of L1 
larvae 
This protocol is used to obtain eggs from an asynchronous culture of adult 
hermaphrodite worms that will hatch to produce a culture of synchronized L1 larvae. 
It is generally used when a mutant worm strain lays eggs poorly, such as strains 
harboring null mutations in the Ets family transcription factor lin-1, or any strain with 
a Vulvaless phenotype. 
o Grow worms as usual on a standard 60-mm stock 2% NGM plate seeded 
with OP50 bacteria, until the plate is overgrown with adult worms.  Unlike 
the egg-laying assay, to obtain enough worms from the bleaching 
protocol, it is necessary to start with 2 overgrown 60 mm plates of stock 
worms per 4 wells of each 6 well plate. 
o Add 2 ml of sterile 1X M9 solution to the plate. Use a sterile Pasteur 
pipette to transfer the worm suspension to a 15 ml conical tube. 
o Spin 30 s in a clinical centrifuge (~1000 RPM) and remove the 
supernatant. 
o Add 5 ml of freshly made alkaline buffer (bleach solution).  This kills all 
adult animals, but leaves eggs (protected by shells) alive, thus producing 
a culture of animals that are all within a ~12 h developmental time window. 
It is important to make the bleach solution fresh for each experiment in 
order to assure good lysis of the adult worms. 
o Incubate at room temperature for 3 min, with occasional gentle agitation.  
o Quickly repeat the centrifugation step and remove the supernatant. 
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o Add 5 ml of 1X M9 buffer (this step MUST be completed within 5 min of 
the addition of alkaline buffer) to resuspend the eggs.  Mix, spin, and 
remove supernatant. 
o Repeat this wash step twice by adding 5 ml of 1X M9 buffer each time. 
o At the final wash step, leave ~50 µl of 1X M9 buffer in the tube and 
resuspend the eggs in it. 
o Use a Pasteur pipette to distribute a few drops of the suspension 
containing the eggs (and adult worm carcasses) to each well containing 
inhibitor or vehicle.  Similar to the egg-laying assay above, it is not 
necessary to distribute exactly the same number of eggs into each well, 
because the data are collected as percentages of all worms in the well 
displaying a given phenotype, rather than absolute numbers of worms in 
the well. 
o Place the plates, again in a sealed plastic container, at 20˚C (or a viable 
temperature appropriate for the strain) and continue as with the egg-laying 
assay above, until the worms reach the desired developmental stage for 
scoring.   
3.7  Mounting worms for DIC microscopy 
This mounting procedure creates a small “pad” of anesthetic-containing agar 
on a microscope slide, onto which the animals can be placed before a cover slip is 
applied.  It is necessary to do this to immobilize the worms in order to score their 
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phenotypes by using Differential Interference Contrast (DIC/Nomarski) optics.  When 
ready to score worms: 
o Melt one aliquot at a time of 3% NGM agar by placing the glass tube first 
into a 100˚C block, then partially cool by transferring it to 65˚C.  Once an 
aliquot has been melted, any excess should be discarded. 
o Add 1 M sodium azide, which will serve as an immobilizing agent for the 
worms, to a final concentration of 10 mM. Vortex briefly to mix.  
o On both sides of a clean slide place two “spacer” slides, each of which 
have a single piece of laboratory tape running the length of the slide. The 
thickness of the labeling tape will determine the thickness of the agar pad.  
To the center slide add two drops of the melted agar with a Pasteur 
pipette, avoiding bubbles. Immediately, drop another clean slide crosswise 
on it.  Allow the agar to solidify and then remove the top slide, thereby 
uncovering the resulting agar pad.  
o Add 5 µl 1X M9 buffer to the top of the agar pad. 
o With a pick, collect the worms to be scored and gently swish them off into 
the buffer solution on the pad.   
o Immediately and gently place an appropriate coverslip on top of the agar 
pad.  For the Nikon Eclipse DIC microscope we use for these 
experiments, a No. 1.5 (18 mm square) coverslip is recommended. 
o If a long session (> 1 h) is planned, seal the edges of the cover slip with 
petroleum jelly or VALAP to avoid desiccation. 
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4.  Scoring wild-type versus Muv phenotypes 
Accurate quantification of the Muv phenotype of animals treated with vehicle 
or inhibitor requires understanding how to identify the ventral protrusions or 
invaginations that represent pseudovulvae, and consistently applying these criteria 
at the appropriate developmental stage.  It is also important to recognize that 
throughput is inversely related to resolution.  Thus, rapid, high throughput scoring is 
possible at low resolution by using a dissecting microscope, and slow, low 
throughput scoring is possible at higher resolution by using DIC/Nomarski optics, but 
it is not possible to achieve both high throughput and high resolution.  Therefore, a 
reasonable sized assay will include 4 or 5 conditions (i.e., four or five plates) for 
worms that will be scored under a dissecting microscope, or 1 or 2 conditions for 
worms that will be scored under a DIC microscope. 
Criteria for distinguishing Muv animals from wild-type (WT) animals always 
include the appearance of one or more ventral protrusions in Muv animals, that is, 
pseudovulvae, or their precursors, that are in addition to the normal WT vulva 
(Figure. 2 and 4).  However, the ease and manner of detecting these pseudovulvae 
may differ, depending on the strain of worms being tested. Worm strains displaying 
robust Muv phenotypes at the adult stage of development, for example, ras/let-
60(n1046gf) mutants, can be rapidly and accurately scored under the dissecting 
microscope, allowing one person to score large samples (hundreds of worms) in a 
single day.  Because the vulva and pseudovulvae are easily observed through the 
dissecting microscope only at the adult stage, it is critical that all the scoring done 
simply by counting these protrusions be performed only on adult worms, and thus 
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the experiment must be timed accordingly. At 20˚C, the time from egg laying to 
adulthood is approximately 60 hours (Brenner, 1974), though certain sickly strains 
can take longer, so their developmental timing must be measured empirically.   
Data should be collected not only on the numbers of worms that are WT vs 
Muv, but also on the numbers of protrusions that appear in the Muv worms:  Muv +1, 
Muv+2, Muv+3, etc. (see Figure. 4).  This is because some inhibitor treatments may 
reduce the percentage of worms that are Muv, whereas others simply reduce the 
numbers of protrusions in Muv worms, and still others do both. This situation is 
analogous to anchorage-independent growth assays using mammalian cells, in 
which either colony number or colony size or both can be affected.  For an example, 
see our recent analyses of Raf and MEK inhibitors in human tumor cell lines (Hao et 
al., 2007). The biological mechanisms underlying these different effects remain 
unclear, however.  
While some mutant strains displaying a Muv phenotype, such as let-60(gf), 
are easily scored on the dissecting microscope, there are other strains of worms that 
display a Muv phenotype but that cannot be scored by this means.  An example of 
such a strain is the lin-1(null) mutant (Table I), mentioned earlier in the context of 
poor egg-laying that necessitates the use of the bleaching protocol to obtain 
synchronous populations of L1 larvae.  The lin-1(null) mutant worms are relatively 
unhealthy in other ways as well.  These worms can undergo significant 
developmental delays (more than 3 days) and become unsynchronized, which 
causes the scoring process to be both less efficient and less accurate. In addition, 
vulval protrusions are poorly distinguished in adult lin-1(null) mutant worms. 
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Therefore, instead of scoring treated lin-1(null) worms at the adult stage, they should 
be scored at the earlier L4 larval stage.  Although highly accurate, this procedure is 
considerably more complex and time-consuming than counting very obvious 
protrusions under the dissecting microscope. 
The numbers of ventral protrusions that will be present at the adult stage 
(Figure 4, top row) can be measured very accurately at the L4 stage by counting 
under high resolution DIC microscopy the structures formed at that point by the 
vulval precursor cells (VPCs) (Figure 4, bottom row) (Sulston and Horvitz, 1977).  
When worms are scored under DIC, the main (wild type) pre-vulval structure can be 
differentiated easily from the additional ventral protrusions or invaginations that are 
seen in adult or L4 worms, respectively, that display a Muv phenotype. VPCs are 
induced by the Ras>MAPK pathway, and the VPCs that will form the WT vulva first 
form a “Christmas tree”-like structure.  In contrast, those cells inappropriately 
adopting vulval fates, because of activating mutations or excess activity in this 
pathway, form a rounded, generally asymmetrical invagination that will eventually 
become a ventral protrusion or pseudovulva (Figure 4).  The high resolution of DIC 
microscopy thus makes possible easy and accurate identification and distinction of 
the invaginations that will become either  the normal vulva or the pseudovulvae. 
However, the processes of worm synchronization and mounting that are required 
prior to quantification at the DIC microscope make this scoring method rate-limiting, 
due to the low number of worms that can be analyzed at one sitting (<100 worms per 
experiment).  In unhealthy worm strains, loss of synchronous growth is common.  
Therefore, not all worms present will be at the appropriate developmental stage 
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suitable for scoring.  To achieve the best accuracy, it is always important to count as 
many worms as are present at the appropriate (in this case, L4) developmental 
stage.               
   73 
   
 
 
 
 
Figure 2.4 Quantification of vulval induction through the Ras>Raf>ERK MAPK 
pathway at adult and L4 larval stages. In the adult worm (top row), the Muv 
phenotype of the activated Ras homolog let-60(n1046gf) is very robust and is easily 
identifiable by the appearance of one or more of the excess ventral protrusions 
called pseudovulvae (black arrows; Muv1, Muv2, Muv3, etc.) that develop in addition 
to the normal wild-type vulva (white arrows). The Muv phenotype of these worms 
can be scored easily and rapidly by simply counting the pseudovulvae present at the 
end of a standard egg-laying assay. In some sickly mutant strains with a Muv 
phenotype, such as lin-1(null) worms, pseudovulvae are hardly distinguishable in 
adults. These worms must be subjected to the bleaching protocol and the Muv 
phenotype quantified instead at the L4 larval stage (bottom row), utilizing DIC 
microscopy. In L4 worms the future wild-type vulva appears as a ‘‘Christmas tree’’ 
structure (white arrow), whereas future pseudovulvae (black arrows) form 
characteristic rounded and frequently asymmetric invaginations. All images were 
obtained using DIC microscopy at 400 x magnification. 
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5.  Proof-of-principle experiment 
We show here a proof-of-principle experiment designed to demonstrate the 
utility of this protocol for evaluating pharmacological inhibitors of activated Ras 
pathway function.  The widely used and well-characterized MEK inhibitor U0126 is a 
potent and selective small molecule inhibitor of both of the dual specificity kinases 
MEK1 and MEK2; it blocks MEK-induced phosphorylation and activation of ERK 
MAPKs both in mammalian cells and in in vitro enzymatic assays (Duncia et al., 
1998).  U0126 should thus inhibit the Muv phenotype of worm strains in which the 
activating mutation is at or upstream from MEK (in C. elegans, MEK-2; see Figure 1 
and Table I), but should not affect the Muv phenotype of worms in which the 
activating mutation is downstream of MEK.  We therefore tested the ability of U0126 
to inhibit the Muv phenotype of worm strains with mutations affecting either Ras or a 
downstream (transcription factor) step in the Ras>Raf>MEK>ERK MAPK pathway. 
As indicated in the protocol described previously, we diluted both the DMSO 
vehicle and the U0126 inhibitor to equivalent concentrations in sterile M9 buffer, 
applied the working dilutions to separate wells containing NGM agar, and added a 
lawn of OP50 bacteria.  We then performed an egg-laying assay in the vehicle- or 
inhibitor-impregnated agar, using let-60(n1046gf) worms expressing an 
endogenously activated LET-60 mutant protein (G13E).  This mutation causes 
activation of the LIN-45-MEK-2-MPK-1 MAPK pathway and hence we expected it to 
be sensitive to Muv inhibition by U0126.  To make sure that any Muv inhibition seen 
was mechanism-based and not just due to general VPC toxicity, we also grew L1 
larvae following a bleach hatch of lin-1(null) worms lacking an Ets-like inhibitory 
   75 
transcription factor that regulates the induction of VPCs (recall that the Muv 
phenotype of lin-1(null) worms must be evaluated following bleach hatch-off due to 
poor egg-laying properties).  Because the Muv phenotype of these worms is driven 
instead by alterations at the transcription factor level, which is clearly downstream of 
MEK-2 (Figure 1 and Table I), we expected it to be insensitive to MEK inhibition. 
The IC50 of U0126 for MEK1 in vitro was reported to be ~0.07 µM, and ~1 µM 
in COS-7 cells (Duncia et al., 1998).  Although it is not clear whether there is a 
definable relationship between the IC50 of U0126 or other inhibitors as identified in 
vitro or in mammalian cell systems and an effective dose in C. elegans, this 
information on U0126 did provide us with a starting point to select doses for assay in 
vivo.  Knowing that the presence of their cuticle barrier means that worms do not 
efficiently take up most small molecules, we chose to test U0126 at 1, 3, 10 and 30  
µM. Treatment with U0126 reverted the Muv phenotype of let-60(gf) worms in a 
dose-dependent manner (Figure 5). The IC50 of U0126 in this strain was ~7 µM, and 
~30 µM was required to completely block the Ras>MAPK signaling pathway.  By 
contrast, even 30 µM had no effect whatsoever on the Muv phenotype of lin-1 null 
animals (Figure 5, top).  These results demonstrate that the Muv inhibition by U0126 
was selective, and are consistent with the mechanism of U0126 acting as a MEK 
inhibitor.  In additional experiments (not shown) using worm strains expressing other 
activating mutations, U0126 also acted as expected, by completely blocking the Muv 
phenotype induced by the activated Raf ortholog, LIN-45(AA), but not by the ERK 
MAPK ortholog, MPK-1.  Although U1026 is a highly specific non-ATP-competitive 
inhibitor of MEK activation of ERK (Ahn et al., 2001; Davies et al., 2000), it has poor 
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pharmacologic properties, and newer generation MEK inhibitors are now under 
clinical evaluation (Roberts and Der, 2007).  If their anti-MEK activities are also 
mechanism-based, we would expect similar results, albeit perhaps at a shifted dose 
range.  However, off-target effects may not be shared with U0126, and may be 
identifiable by these assays as was seen with the unexpectedly pro-apoptotic FTIs 
(Lackner et al., 2005).   The same type of experiments as we have described here can be applied to 
previously characterized or novel inhibitors of Ras function, or to inhibitors of other 
pathways, by utilizing appropriate strains of worms.  Consult Table I for additional 
information about available worm strains with activating mutations in signaling 
components that function both upstream and downstream of Ras.  These strains 
provide more focused systems to study inhibitors that target the Ras signaling 
network at distinct nodal points. 
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Figure 2.5 The MEK inhibitor U0126 dose dependently reduces the Muv phenotype 
induced by constitutively activated Ras in let-60(n1046gf) worms (top, green), but 
does not affect the Muv phenotype induced by loss of the downstream Ets family 
transcription factor in lin-1(null) animals (top, red).‘‘Percent baseline’’ refers to the 
percentage of animals displaying a Muv phenotype in the presence of inhibitor 
compared to vehicle-only control. The dose-response curve (bottom) demonstrates 
that the IC50 for Muv inhibition in let-60(gf) worms is approximately 7.1 µM, and 
essentially maximal inhibition can be achieved at the 30 µM dose to which lin-1(null) 
worms are insensitive. 
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VI.  Conclusions and future directions   
Despite intensive efforts by researchers and the pharmaceutical industry to 
develop inhibitors of Ras for molecularly-targeted therapeutics, to date no anti-Ras 
therapeutics have made the successful passage through the long and winding road 
of drug discovery.  The inability to identify pharmacologic approaches that selectively 
target mutationally activated Ras directly has contributed to this failure, with the most 
advanced efforts targeting proteins that are involved in the posttranslational lipid 
modification of Ras (FTase) or signaling components downstream of Ras (Raf and 
MEK).  Because FTase activity is critical for the function of >50 other human proteins 
(Reid et al., 2004), and since the Raf>MEK>ERK pathway is not the simple linear 
cascade that we once imagined (McKay and Morrison, 2007), inhibitors of these 
proteins may have considerable off-target activities and cellular consequences.  Our 
validation and application of inhibitor analyses of Ras signaling in C. elegans 
provides another model system for ongoing and future development of anti-Ras 
inhibitors. Overall, this genetic system, together with more physiologically relevant 
preclinical models of cancer, including new human cell culture and genetically-
engineered mouse models (Hahn and Weinberg, 2002; Sharpless and Depinho, 
2006), will produce improved preclinical analyses to facilitate greater clinical success 
for target-based drug discovery. 
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ABSTRACT 
 
 
Background 
In mammals, activation of the Ras-Raf-MEK-ERK MAPK signaling cascade 
promotes cellular proliferation, and activating mutations in Ras are implicated in the 
onset and maintenance of numerous cancers. In C. elegans, this pathway is highly 
conserved and is required for proper development.  Gain-of-function mutations in the 
Ras homolog LET-60 (let-60(gf)) lead to constitutive signaling through this pathway 
and result in a multivulva (Muv) phenotype. MCP compounds were originally 
identified in a yeast two-hybrid screen for their ability to disrupt Ras-Raf interactions 
in that system, and have been shown to block Ras- and, in some cases, Raf-
mediated biological activities in mammalian cells.  Whether their biological activity is 
a consequence of interfering with the Ras-Raf interaction has been unclear.  The 
purpose of this study was to use the easily-scored Muv phenotype as an accurate in 
vivo readout to characterize the selectivity of MCP110 and its analogs, which are 
novel putative Ras/Raf interaction inhibitors, for blockade of Ras-Raf function, and to 
determine whether impaired output of the Ras-MAPK pathway upon MCP treatment 
is linked to impaired interaction between Ras and its effector Raf. 
 
Results 
We first evaluated the effects of MCP compounds on the Muv phenotype in 
worm strains harboring mutations in genes at different levels of the Ras-MAPK 
pathway.  Our genetic analyses showed that MCP compounds caused a significant 
dose-dependent reduction of Muv in worm strains with activating mutations in the 
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homologs of Ras (LET-60) or Raf (LIN-45), but not in worm strains with activating 
mutations in the MAP kinases MEK-2/MPK-1 or the Ets-like transcription factor LIN-
1.  Thus, these inhibitors selectively impair pathway function downstream of Ras and 
upstream of or at the level of Raf, consistent with disruption of a protein-protein 
interaction between Ras and Raf leading to decreased signaling from the Ras-MAPK 
pathway.  Inhibition of the protein-protein interaction has not been confirmed in 
mammalian cells with full length, fully processed proteins. Therefore, in 
complementary studies, we also analyzed the ability of MCP compounds to disrupt 
Ras-Raf interactions in mammalian cells.  First, in pulldown assays with the Ras-
binding domain of c-Raf-1 (Raf-RBD), MCP110 treatment caused a reduction in 
pulldown of Ras when using the Raf-RBD, confirming that MCP110 blocks the 
physical interaction of Ras and Raf.  In addition, we demonstrated MCP110-
mediated disruption of the Ras/Raf-RBD interaction by a dose-dependent 
displacement of a fluorescent-tagged Raf-RBD probe, from plasma membrane 
locations of active Ras, to the cytosol and other compartments.  Finally, decreases 
in active, phosphorylated ERK1/2 upon MCP treatment of the same cells 
demonstrated MCP-mediated functional impairment of Ras-Raf-MEK-ERK signaling. 
 
Conclusions 
We have effectively utilized the worm as an in vivo genetic system to evaluate 
the activity and selectivity of inhibitors designed to target the Ras-Raf-MAPK 
pathway.  We have demonstrated the ability of MCP110 to disrupt, at the level of 
Ras/Raf, the Muv phenotype induced by chronic activation of this pathway in C. 
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elegans as well as the physical interaction between Ras and Raf-RBD in mammalian 
cells.  Thus, pharmacological inhibition of the interaction between Ras and Raf is an 
effective means of altering a worm developmental program that depends on Ras-
Raf-MAPK signaling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   84 
INTRODUCTION 
 
Over the past two decades, there have been many attempts to isolate and 
characterize pharmacological inhibitors targeting Ras-dependent signaling 
pathways.  The small GTPase Ras normally transmits signals downstream of 
diverse inputs and is a critical signaling node for many cellular activities.  Aberrant 
Ras activity leads to the deregulation of numerous cellular processes including 
proliferation, survival, cell adhesion and migration, that in turn can contribute to 
cellular transformation, invasion and metastasis (Campbell and Der, 2004), and Ras 
is mutationally activated in ~30% of cancers (Bos, 1989).  Among the downstream 
effectors of Ras, the most well-characterized is the Ras-Raf-MAPK signaling 
pathway, in which Ras interaction with the serine/threonine kinase Raf causes a 
cascade of kinase activation, with Raf activating the mitogen-activated protein 
kinase kinases (MAPKK, or MEK) and MEK activating the ERK MAPK, which then 
translocates to the nucleus to phosphorylate and activate transcription factors to 
carry out the commands of Ras.  The B-Raf isoform is mutationally activated, most 
commonly at V600E, in tumors including colorectal cancer, malignant melanoma and 
thyroid cancer (Davies et al., 2002; Garnett and Marais, 2004), in a manner mutually 
exclusive with oncogenic Ras. Aberrant activation of MAPK has also been 
associated with various cancers (Wagner and Nebreda, 2009). 
Given the relevance of the Ras-Raf-MAPK signaling pathway to a wide array of 
malignancies, there has been a great deal of interest in developing anti-cancer 
therapeutics by targeting specific elements of this pathway (Cox and Der, 2002; 
Khazak et al., 2007; Roberts and Der, 2007; Sebolt-Leopold and Herrera, 2004).  
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Despite intensive efforts (Blum et al., 2008), it has proven very difficult to selectively 
target Ras itself, which at present is widely viewed as “undruggable” due to the 
picomolar affinity of GTP for Ras. Pharmacological inhibition of the Raf and MEK 
kinases has been seen as more tractable, and several putative Raf inhibitors have 
reached clinical trials, including both antisense and kinase inhibitors. The most 
prominent of these, BAY43-9006 (sorafenib), was originally described as a Raf 
kinase inhibitor (Lee and McCubrey, 2003; Lyons et al., 2001), but its activity in 
cancer patients did not correlate with Raf activation or mutational status.  Instead, it 
demonstrated additional activity towards the pro-angiogenic vascular endothelial 
growth factor receptors (VEGFR)-2 and -3, and to other receptor tyrosine kinases 
such as PDGFR-beta that are also involved in tumorigenesis (Wilhelm et al., 2004) 
(Wilhelm et al., 2006). In a phase I clinical trial, the partial responses seen in renal 
cell carcinoma (RCC) patients, whose tumors have high VEGFR expression and are 
dependent on VEGFR signaling, led to additional testing of this inhibitor in this 
selected group of patients and eventually to its approval for the treatment of patients 
with advanced RCC (Wilhelm et al., 2006) (Khazak et al., 2007).  Thus, the anti-
tumor effects of sorafenib, now known as a “multikinase inhibitor”, are at least partly 
mediated by blockade of VEGFR kinase rather than Raf kinase.  Newer Raf kinase 
inhibitors such as PLX4032  (Sala et al., 2008) and its later derivatives, intended to 
be selective for mutationally activated B-Raf (V600E) are also under development 
(Tsai et al., 2008).  Extensive investment has also been made in MEK inhibitors 
including CI-1040, AZD6244 and others (Friday and Adjei, 2008; Khazak et al., 
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2007) (Cox and Der, 2002) (Roberts and Der, 2007), although none has yet proven 
efficacious as single agent therapy.  
Another approach to inhibit the Ras-Raf-MAPK signaling pathway is through 
protein-protein interaction (PPI) inhibitors. Given that an individual kinase generally 
has multiple substrates, an advantage of PPI inhibitors over kinase inhibitors is that 
they may be more selective towards a specific target, although this may be less of a 
problem for Raf proteins, which target primarily MEK.  Challenges arise for PPI 
inhibitor development due to the relative lack of small-molecule starting points for 
drug design, the typical flatness of the protein-protein interface, the difficulty of 
distinguishing real from artefactual binding, and the size and character of typical 
small-molecule libraries (Arkin and Wells, 2004).   Despite these challenges, there 
are ongoing efforts both to use traditional screening methods and also to design 
better strategies by using computer-generated systems to assess the targeting 
potential of protein-protein interactions and thence to isolate novel PPI inhibitors 
(Sugaya and Ikeda, 2009). Such efforts have led to the successful identification of 
several PPI inhibitors, of which only a few have reached clinical evaluation. 
Examples of protein-protein interactions for which inhibitors have been identified 
include the cytokine interleukin-2 (IL-2) with the α chain of IL-2 receptor (IL-2Rα), 
Bcl-2/Bcl-XL with the pro-apoptotic molecule BAK, the human protein double minute 
2 (HDM2) interaction with the tumor suppressor p53, and the ATP-dependent 
chaperone protein HSP90 with the cochaperone Hsp organization protein (HOP) 
(Arkin and Wells, 2004; Arkin and Whitty, 2009; Wells and McClendon, 2007).  
Concurrent with these developments has been the search for PPI inhibitors of the 
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interaction between the small GTPase Ras and the serine/threonine kinase Raf 
(Khazak et al., 2007).  
Here, we characterized the activity of a novel family of putative Ras/Raf 
interaction inhibitors derived from such a search.  MCP compounds such as MCP1, 
MCP110 and MCP122 were originally isolated from a small molecule library using a 
dual-bait two-hybrid system to probe the interaction between Ras and Raf (Kato-
Stankiewicz et al., 2002; Khazak et al., 2005; Lu et al., 2004). Earlier reports 
characterizing the activity of these agents showed their ability to inhibit Ras signaling 
and Ras-mediated cell proliferation and anchorage-independent growth in cell-based 
systems, as well as transformed growth in nude mouse xenografts (Campbell et al., 
2007; Kato-Stankiewicz et al., 2002; Skobeleva et al., 2007).  However, the 
mechanism of action of these putative Ras/Raf interaction inhibitors is not 
completely understood.  The ability of MCP1 and later analogs such as MCP110 to 
inhibit Ras- but not Raf-mediated transformation in fibroblasts, colorectal cancer cell 
lines and melanoma cell lines suggested that their action was at the level of Ras 
rather than Raf, but more recent evidence indicated that MCP compounds also have 
activity towards melanoma cell lines in which B-Raf is mutated (Hao et al., 2007).  
Therefore it is unclear whether the anti-transformation activity of MCP compounds is 
due to blocking Ras, Raf or yet another target.  Whether MCP compounds directly 
disrupt the physical interaction between Ras and Raf, as shown by the yeast two-
hybrid assay in which they were originally identified, has not been confirmed in 
mammalian cells.   
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Characterizing the precise mechanism of action of PPI inhibitors is a 
challenging task, especially given the difficulty of determining whether a given 
compound is interacting with the interface of one protein versus the other. There are 
no structural analyses available to reveal whether MCP compounds bind physically 
to Ras, to Raf, or to both.  We therefore set out to determine at what level in the 
pathway MCP compounds act, by using epistasis analyses in the nematode 
Caenorhabditis elegans, a tractable genetic model system for the in vivo evaluation 
of Ras pathway drug activity 
C. elegans has served as a very useful model organism to study development, 
neurobiology and many other biological processes.  Recently it has also been useful 
in pharmacogenetic studies to identify the targets of pharmacological agents 
(Lackner et al., 2005). The C. elegans Ras-Raf-MAPK signaling pathway is highly 
conserved, from the EGF ligand to the transcriptional output (Moghal and Sternberg, 
2003; Reiner et al., 2008). LET-60, the worm ortholog of Ras, is critical to regulate 
vulval development (Beitel et al., 1990), and excessive activation at any level of the 
pathway results in hyperinduction of vulval tissue, leading to a Multivulva (Muv) 
phenotype.  For example, a glycine to glutamic acid mutation at residue 13 (G13E) 
of LET-60, the worm ortholog of Ras, results in a gain-of-function that produces a 
constitutively activated LET-60 protein, analogous to the well known Ras(G12V) 
mutation in mammalian cells.  Not surprisingly, then, LET-60(G13E) is well 
documented to induce the Muv phenotype (Beitel et al., 1990), as do transgenes 
bearing activated Raf (LIN-45) or MEK/MAPK (MEK-2/MPK-1) and loss-of-function 
mutations in the downstream Ets-like transcription factor LIN-1 (Ferguson and 
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Horvitz, 1985) (Chong et al., 2001) (Rocheleau et al., 2005) (Beitel et al., 1995; 
Lackner and Kim, 1998).  Previous work by our group and others has validated 
these transgenes and the Muv phenotype of C. elegans as in vivo readouts to 
evaluate the activity of pharmacological inhibitors of the Ras-Raf-MEK-ERK pathway 
(Hara and Han, 1995; Reiner et al., 2008) and to identify pharmacological targets 
(Lackner et al., 2005).  We therefore selected this system to characterize the activity 
and selectivity of known and novel MCP compounds. 
 We first confirmed that MCP110 acts downstream of Ras/LET-60 and 
upstream or at the level of Raf/LIN-45, as would be expected for an inhibitor of the 
Ras/Raf interaction. In addition, we demonstrate here that the previously 
uncharacterized MCP110 analog, MCP116, but not MCP146, also inhibits Ras/LET-
60 signaling and displays specificity comparable to MCP110. Finally, for the first time 
we show evidence in mammalian cells that MCP110 disrupts not only signaling from 
Ras to ERK but also the physical interaction between Ras and Raf, and have 
narrowed the interface on Raf to the Ras-binding domain. 
 
RESULTS 
The C. elegans Ras signaling pathway as a platform for analysis of small 
molecule inhibitors  
We have previously established the multivulva (Muv) phenotype of the 
nematode worm C. elegans as an in vivo model system to study the action of 
pharmacological inhibitors targeting Ras-induced signaling cascades.  Specifically, 
we used the well-characterized selective MEK inhibitor, U0126 (Khazak et al., 2005; 
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Reiner et al., 2008) to demonstrate that effective pharmacological inhibition of the 
Ras-Raf-MEK pathways restored a normal phenotype in worms that would otherwise 
display a Muv phenotype based on their genetic background. The Ras-Raf signal 
that controls vulval cell fate in C. elegans is well described at the molecular genetic 
level. Consequently, many genetic reagents, including both in situ mutations and 
transgenic constructs, are available for pharmacological dissection of the Ras 
pathway. In this study, we exploited activated Ras, activated Raf, combined 
activated MEK/ERK, and loss of an Ets transcription factor, all of which result in 
excessive vulval induction. For clarity we refer to these reagents, which are 
described further in the Methods section, as Ras, RafAA, MEK/ERK and Ets. 
In this system, wild type worms have a normal vulva accompanied by no 
ventral protrusions, whereas worms with excessive Ras pathway activity have 
hyperinduction of epithelial cells that result in a Muv phenotype, characterized by 
ectopic nonfunctional pseudovulvae that are visible as ventral protrusions. Both 
phenotypes can be scored under a dissecting stereomicroscope, and can be 
quantified either in a binary manner as Muv or non-Muv(WT), or by the number (0-3) 
of ectopic pseudovulvae. Thus, animals with one or more ventral protrusions are 
scored as Muv, whereas worms with a fully developed vulva but no protrusions are 
scored as wild-type.  Because of the timing of the C. elegans life cycle, the 
consequences of treating worms with pharmacological inhibitors can be quantified 
precisely by scoring the phenotypes of the progeny of the treated worms (Reiner et 
al., 2008).  Here we used this validated system to test the activity and target 
selectivity of small molecules that are putative Ras/Raf interaction inhibitors, 
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MCP110 (Lu et al., 2004) (Kato-Stankiewicz et al., 2002; Khazak et al., 2005; Lu et 
al., 2004) and its novel analogs MCP116 and MCP146. 
To illustrate the phenotypes described above and quantitated in our study, we 
show images of animals grown under different drug conditions (Figure 1A). Wild-type 
animals have a normal vulva (white arrow) and an undisrupted ventral surface. 
Animals expressing activated Ras display the expected Muv phenotype when 
treated with vehicle (DMSO) only. In these worms (center), both the functional vulva 
(white arrow) and three additional ventral protrusions (black arrows) are identifiable. 
In contrast, these animals do not display the typical Ras-induced Muv phenotype 
when treated with MCP110, but rather have a single properly developed vulva and 
no protrusions (right).  Thus, MCP-treated Ras animals have the same appearance 
as wild type animals, consistent with disruption of Ras-Raf-MEK-ERK signaling 
(Reiner et al., 2008). 
 
MCP110 and MCP116, putative Ras/Raf interaction inhibitors, reverse the 
hyper-induced Muv phenotype of worms expressing activated Ras 
We scored the Muv phenotype of animals expressing activated Ras that were 
grown in the presence of MCP inhibitors or DMSO vehicle. Developmentally 
synchronous animals were collected from each treatment group (see Methods for 
details) and the Muv phenotype scored according to the presence and number of 
ectopic pseudovulvae.  Animals displaying a Muv phenotype when drug-treated 
were normalized to the level of hyper-induction of Muv seen in vehicle-treated 
animals, with the baseline for Muv established separately for each genotype. 
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We expected the Muv phenotype to be sensitive to MCP compounds if the 
Ras-Raf interaction was successfully inhibited, and therefore that the progeny of 
these treated worms would display normal vulval development.  As expected, we 
observed (Figure 1B) that animals expressing activated Ras/LET-60  treated with 
MCP110 (20 µM) were approximately 50% less likely than vehicle-treated animals to 
display a Muv phenotype.  Delivery of drug concentrations higher than 20 µM was 
not possible due to MCP compound precipitation. Additionally, we observed that the 
previously uncharacterized MCP110 analog, MCP116, showed inhibitory activity 
similar to that of MCP110. Effects of both MCP110 and MCP116 were dose-
dependent.  In contrast, a third derivative, MCP146, showed no significant activity at 
any tested concentration.  As an additional negative control, we show that treatment 
with the poorly active analog, MCP122 (Hao et al., 2007) (Campbell et al., 2007; 
Kato-Stankiewicz et al., 2002)), had no effect.  Together, these results indicate that 
both MCP110 and MCP116 inhibit the Ras-Raf-MAP kinase pathway downstream of 
Ras activation. This conclusion is consistent with the reported ability of MCP110 to 
inhibit Ras/Raf interactions in yeast and with its biological activities in mammalian 
cells.  
 
MCP compound inhibition of the Muv phenotype is specific to the Ras 
pathway 
We have shown previously (Reiner et al., 2008) that the well-characterized 
MEK inhibitor U0126 suppressed the activated Ras Muv phenotype, but not the Muv 
phenotype conferred by loss of the Ets-like transcription factor.  Therefore, as a 
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control for pathway specificity, to ensure that suppression of the Muv phenotype is 
not indirect, for example by inhibiting the cell cycle, we tested whether MCP 
compounds also inhibited the Muv phenotype of Ets worms. As expected, Ets 
animals were resistant to both MCP110 and MCP116, with no response at any dose 
(Figure 2A). 
MCP compounds act upstream of MEK 
To determine the pathway level at which MCP compounds act, we continued 
our analysis with MEK/ERK (Lackner and Kim, 1998). Epistasis analysis has shown 
that MEK/ERK is independent of upstream signaling from Ras or Raf (Lackner and 
Kim, 1998).  Furthermore, inhibition of MEK alone is sufficient to block the Muv 
phenotype of MEK/ERK (Reiner et al., 2008).  Thus, MEK/ERK animals should also 
be resistant to MCP compounds, which are believed to act by disrupting the Ras/Raf 
interface. As predicted, these animals were also resistant to MCP110, MCP116 and 
MCP146 (Figure 2B), with no significant differences in Muv seen in worms treated 
with MCP compounds versus vehicle treatment. These results show that MCP110 
and MCP116 target the Ras-Raf-MAPK pathway downstream of Ras and upstream 
of MEK. 
MCP compounds inhibit activated Raf 
To determine if MCP compound activity is due to blocking Raf, we compared 
the Muv phenotype of RafAA animals grown in the presence of MCP compounds or 
vehicle.  Surprisingly, treatment of these worms showed that their progeny were 
sensitive to the action of MCP110, and, to a lesser extent, MCP116 and the poorly 
active derivative MCP146 (Figure 3). Reversion of the Muv phenotype in these 
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animals by MCP110 was dose-dependent and occurred with similar potency as in 
the Ras strain.  This result suggested that MCP110 inhibition of Muv induction 
occurred at the level of Raf, rather than Ras. RafAA has been speculated to be Ras-
independent (Rocheleau et al., 2005; Yoder et al., 2004). However, this Raf 
ortholog, although constitutively activated and sufficient to drive the Muv phenotype, 
still includes the Ras-interacting domains RBD and CRD (Chong et al., 2001). It is 
possible that, in C. elegans, full activation of LIN-45AA requires a contribution from 
endogenous Ras. Further, given that MCP116 robustly inhibited Ras but not Raf 
induction of the Muv phenotype, it is possible that they do not bind in exactly the 
same manner to the Ras/Raf [Ras/RafAA] interface.   
To determine whether Ras binding to Raf is required for Raf activation, we 
attempted several different approaches to developing new activated Raf transgenes 
that are Ras-independent.  First, we attempted to engineer a transgenic strain 
expressing LIN-45 that was constitutively activated by the addition of the 
hypervariable and CAAX sequences from C. elegans LET-60/Ras, which is a 
validated method for constitutive activation of Raf (Leevers et al., 1994; Stokoe et 
al., 1994). However, this transgene induced no Muv activity (data not shown).  We 
also attempted to generate a C. elegans version of the Raf(22W) N-terminally 
truncated protein, which is Ras-independent because it lacks both the RBD and 
CRD domains and which is known to be constitutively active in mammalian cells 
(Stanton et al., 1989).  However, the protein products of this and other N-terminally 
truncated lin-45 mutants were not expressed, for reasons that remain unclear but 
may be related to decreased protein stability (data not shown).  Therefore we cannot 
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yet definitively answer the questions of whether MCP110 reverts the Muv phenotype 
of RafAA-expressing animals by acting at the level of Ras or Raf, or whether 
MCP110 and MCP116 bind to Ras or Raf in the same manner.  These questions will 
likely require structural information that is not yet available. 
 
MCP110 inhibits the physical interaction between Ras and Raf in mammalian 
cells 
Another possibility to explain the ability of MCP110 to inhibit the Muv 
phenotype of LIN-45AA-expressing worms is that this action does not occur as a 
consequence of disruption of the Ras/Raf interface.  To confirm that MCP110 can in 
fact disrupt the Ras-Raf interaction, we turned to mammalian cells where 
biochemical analyses are more tractable.   
The initial screening strategy for MCP compounds relied on the ability of the 
screened library components to separate the interaction of Ras and Raf in a yeast-
two hybrid assay utilizing full-length versions of H-Ras and Raf-1 (Kato-Stankiewicz 
et al., 2002; Khazak et al., 2005).  It remains unclear if the activity of MCP1, the 
originally identified MCP pharmacophore, relied on interaction with the Ras or the 
Raf protein interface.  To answer this question for MCP110, we took advantage of 
the fact that activated, GTP-bound Ras binds to Raf via interaction between its own 
effector domain (core residues 32-40 as well as flanking sequences) and the Ras 
binding domain (RBD) and cysteine-rich domain (CRD) of Raf.  The affinity of the 
Raf RBD for active Ras-GTP has been exploited to generate a widely used probe for 
this interaction, designated Raf-RBD, which is composed of residues 51-131 in the 
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amino-terminal regulatory region of Raf-1.  A GST-fusion protein of Raf-RBD [GST-
Raf-RBD] has long been used as an affinity for pulldown assays to retrieve and 
quantitate the levels of activated Ras in cell lysates (de Rooij and Bos, 1997; Taylor 
and Shalloway, 1996).  More recently, we have used YFP- or GFP-tagged Raf-RBD 
as a visual probe for the subcellular localization of active Ras (Bivona et al., 2006; 
Chiu et al., 2002).  In each case, the readout is dependent on the physical 
interaction between Ras and Raf-RBD. Thus, to further understand the mechanism 
of action of MCP110 we analyzed its ability to disrupt the interaction between 
activated Ras and the Raf-RBD in a cell-based system.  
We first performed pulldown assays in NIH 3T3 cells transiently transfected 
with both a constitutively active form of Ras [H-Ras(G12V)] and with GST-Raf-RBD.  
Briefly, GST-Raf-RBD coupled to GSH-agarose beads was used to retrieve active 
Ras from lysates of cells treated with vehicle or MCP110 (see Methods), and the 
pulled-down Ras was then detected by immunoblot analysis. We observed that the 
physical interaction between Ras and the Raf-RBD interaction was disrupted by 
MCP110 in a dose-dependent manner, but not by the vehicle negative control 
(Figure 3.4A, top panel).  To confirm that less Ras was retrieved in the presence of 
MCP110 due to less effective interaction of Ras with the Raf-RBD rather than due to 
poor expression, we also assessed the total levels of Ras from equivalent amounts 
of lysates.  We observed that Ras protein expression did not decrease upon 
MCP110 treatment (Figure 3.4A, lower panel), indicating that Ras was still available 
for pulldown but was not retrieved.   
   97 
If MCP110 decreased the physical interactions between Ras and Raf, it 
should also decrease downstream signaling through the Ras-Raf-MAPK pathway.  
We therefore examined the levels of phosphorylated ERK1/2 (p-ERK1/2) by 
immunoblotting with a phospho-specific antibody for ERK1/2 proteins that are 
phosphorylated at threonine 202 and tyrosine 204.  Consistent with the dose-
dependent inhibition of the Ras-Raf interaction, p-ERK levels (Figure 3., upper 
panel) were also reduced in a dose-dependent manner upon addition of MCP110 
but not vehicle, while the total levels of ERK remained unaffected (Figure 3.4B, 
lower panel). Together, these results indicate that MCP110 can inhibit the physical 
interaction between Ras and Raf, as well as at least one functional consequence of 
that interaction, namely signaling to the downstream effector MAP kinases, ERK1/2.  
They also demonstrate that interaction of Ras with the Raf-RBD alone can be 
impaired by MCP110, consistent with the possibilities that the MCP110-mediated 
inhibition of the Muv phenotype induced in C. elegans by the LIN-45AA mutant Raf 
ortholog that retains the RBD may be due to MCP110 binding to either Ras/LET-60 
or to Raf/LIN-45.  These possibilites cannot be distinguished at present. 
 
MCP110 impairs localization of Raf-RBD to the plasma membrane in cells 
expressing constitutively active Ras 
To corroborate our findings that MCP110 disrupted the physical interaction of 
Ras with the Raf-RBD, with a consequent functional impairment of downstream 
signaling, we wished to evaluate this interaction by another approach.  As mentioned 
above, one biologically relevant method for doing so is to visually monitor the 
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localization of a fluorescently tagged Raf-RBD.  We have previously utilized Raf-
RBD tagged with yellow fluorescent protein (YFP-Raf-RBD) to probe the subcellular 
localization of activated Ras (Bivona et al., 2006).  We therefore used this probe in 
NIH 3T3 cells treated with vehicle or MCP110 to compare the localization of the Raf-
RBD with that of a constitutively active, HA-tagged Ras, which was detected by 
Alexa-Fluor594-conjugated secondary antibody directed against the epitope tag. 
Cells were scored according to whether the YFP-Raf-RBD probe was localized to 
one of three major subcellular distributions:  primarily membranes including plasma 
membrane; internal membranes and cytosol; or cytosol and nucleus. 
In cells expressing the YFP-Raf-RBD probe along with empty vector, YFP-
Raf-RBD displayed a diffuse distribution throughout the cytosol and nucleus 
(representative images are shown in Figure 3.4C and quantitation is shown in Figure 
3.4D).  In stark contrast but as expected (Bivona et al., 2006), co-expression of 
constitutively activated Ras resulted in exclusion of YFP-Raf-RBD from the nucleus 
and strong recruitment of Raf-RBD to membrane sites of Ras localization such as 
the plasma membrane and internal membrane compartments (Figures 3.4C and 
3.4D, vehicle treatment).  Consistent with the ability of MCP110 to dose-dependently 
reduce the amount of Ras pulled down by GST-Raf-RBD (Fig. 4A, upper panel), it 
also dose-dependently impaired the recruitment of YFP-Raf-RBD to sites of 
activated Ras (Figure 3.4C, MCP110 treatment). Indeed, with increasing doses of 
MCP110, YFP-Raf-RBD was restored to the cytosol and the nucleus (Figure 3.4C, 
top row) even as Ras remained membrane bound and nuclear-excluded (Figure 
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3.4C, middle row).  These results are also consistent with MCP110 disruption of the 
physical interaction between Ras and Raf. 
 
DISCUSSION 
MCP110 and MCP116 act downstream of Ras/LET-60 and upstream or at the 
level of Raf/LIN-45 
Putative Ras-Raf interaction inhibitors such as MCP1 or derivatives based on 
MCP1, such as MCP110, have been shown previously to inhibit Ras-induced 
transcriptional reporter activity, cell migration, morphological and growth 
transformation as well as tumorigenicity in nude mice (Campbell et al., 2007; Hao et 
al., 2007; Kato-Stankiewicz et al., 2002).  However, although these small molecules 
were originally identified via a yeast two-hybrid screen for inhibitors of interactions 
between H-Ras and Raf-1 (Kato-Stankiewicz et al., 2002; Khazak et al., 2005; Lu et 
al., 2004), whether their biological activities in mammalian cells are due to physical 
disruption of this interaction has not been shown.  Further, there have been 
conflicting reports in the literature as to whether the presence of mutationally 
activated and therefore Ras-independent B-Raf [B-Raf(V600E)] confers resistance 
to inhibition by MCP compounds (Hao et al., 2007; Kato-Stankiewicz et al., 2002).  
However, these studies focused on different MCP analogs (MCP1 vs MCP110) and 
evaluated their actions in distinct B-Raf(V600E)-expressing melanoma lines, which 
could explain the different results.  Therefore it was also not certain whether MCP 
compounds as a group act at the level of Ras or Raf.   
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Here we have used C. elegans as a genetic tool to investigate the level of the 
Ras-Raf-MAPK pathway at which MCP110 and its novel derivatives MCP116 and 
MCP146 act.  The C. elegans orthologs in this pathway are highly conserved with 
those of mammals, but drive hyper-induction of vulval development in the worm, 
which is read out as a Muv phenotype.  We have shown here that MCP110 and 
MCP116 but not MCP146 inhibit the Muv phenotype driven by a constitutively 
activated LET-60, which is the worm ortholog of Ras, but fail to inhibit the Muv 
phenotype driven by downstream elements of the pathway including MEK/MAPK 
and the Ets-like transcription factor, LIN-1.  These results are consistent with but do 
not prove MCP inhibition of Ras-Raf interactions. The lin-1 null-driven Muv 
phenotype has been used previously by others to demonstrate specificity of first-
generation farnesyltransferase inhibitors (FTIs) gliotoxin and manumycin, which 
target an enzymatic process that occurs upstream of LIN-1 and therefore should not, 
and did not, block Muv driven by LIN-1 deficiency (Hara and Han, 1995).   We have 
used this transgene previously to validate epistatically the actions of the MEK 
inhibitor U0126 in this model (Hara and Han, 1995; Reiner et al., 2008), thus 
supporting the use of the Muv-driven phenotype caused by genetic lesions in 
elements of the Ras-Raf-MAPK pathway as a readout for pharmacological inhibition 
of the pathway.  We also showed here that worms expressing gain-of-function 
transgenes for MEK-MAPK were resistant to inhibition of Muv by MCP analogs, 
consistent with their proposed targeting of the Ras-Raf interface, which is upstream 
of MEK.  However, whether they act at the level of Ras or of Raf still remained to be 
determined. 
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Our analysis of worms expressing an ortholog of constitutively activated Raf, 
LIN-45AA, showed that MCP110 and MCP116 exert activity towards the Muv 
phenotype caused by this activated form of Raf, which was unexpected since it has 
been reported (Yoder et al., 2004) to be Ras-independent and therefore should not 
be sensitive to disruption of the Ras-Raf interaction. Epistasis analysis involving lin-
45AA transgenic worms, in combination with loss-of-function mutations in elements 
upstream of LIN-45 in the pathway, suggested that the Muv phenotype of lin-45AA-
expressing worms is independent of Ras activity (Rocheleau et al., 2005), but this 
was not proven conclusively because Ras/LET-60 itself was still present and 
functional. The mechanisms by which Raf and LIN-45 are activated have been 
extensively reviewed elsewhere (Chong and Guan, 2003; Chong et al., 2001; 
Harding et al., 2003), and it is clear that human and worm orthologs have similar 
regulatory mechanisms.  However, the significant pharmacological inhibition of the 
activated Raf/LIN-45-driven Muv phenotype by MC110 seen here implies that the 
mechanisms by which LIN-45 is activated may still require Ras-Raf interaction.  
Indeed, this protein retains both the Ras-binding domain and CRD and thus has 
room for MCP action on the Ras-Raf interface. Our attempts, like those of many 
others in the C. elegans field, to generate more informative lin-45 transgenes were 
unsuccessful, so whether a truly Ras/LET-60-independent form of Raf/LIN-45 would 
be resistant to inhibition by MCP110 or MCP116 remains to be determined. 
 
The discrepancies in previous observations of MCP activity leaves room to 
consider that the selectivity of these compounds for either Ras or Raf may rely in 
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part on the model system or cell context. The ability of MCP110 and MCP116 to 
inhibit the Muv phenotype in worms expressing activated Ras/LET-60 may be due to 
the 86% identity of LET-60 shared with N-Ras in the first 164 amino acids, which 
allows LET-60 to possess all the biochemical functions of Ras proteins in mammals 
(Han and Sternberg, 1990).  Conversely, some subtle isoform differences may also 
account for apparently discordant results between studies that do not evaluate 
precisely the same players (Fischer et al., 2007).  
While the worm does not replace mammalian cell culture models or higher 
organisms for in vivo studies, the use of a living organism for pharmacological 
studies, especially one that, like C. elegans, has been extensively characterized at 
the developmental and behavioral levels, can also lead to the detection of toxicity 
and off-target activity early in the drug discovery process, as well as to genetic 
identification of the target of unexpected biological activities (Lackner et al., 2005).   
 
MCP110 is a true protein-protein inhibitor of the Ras-Raf-RBD interaction 
The original screen for MCP compounds, described in detail in (Kato-
Stankiewicz et al., 2002; Khazak et al., 2005), involved a modification of the yeast 
two-hybrid assay, which is a standard and powerful technique to detect protein-
protein interactions and was the first method used to identify the interaction between 
Ras and Raf in live cells (Vojtek et al., 1993).  The technique, performed in this case 
in a hyperpermeable strain of yeast to enhance penetration of the cell wall by small 
molecules (Khazak et al., 2005), detects these interactions by the transcriptional 
transactivation of a dual reporter system, and thus it is important for the interactions 
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being analyzed to take place in the cell nucleus.  Normally, Ras is post-
translationally modified by farnesylation at its C-terminus for membrane targeting 
and biological activity, but in order to produce more functional Ras (bait) in the 
nucleus, the C-terminal modification motif was mutated to become insensitive to 
plasma membrane targeting (Khazak et al., 2005).  The alteration of Ras localization 
to fit the purpose of the screen may have had an impact on the outcome, especially 
since it is thought that Raf interacts differently with farnesylated vs nonfarnesylated 
Ras proteins (Williams et al., 2000).  In addition, compounds registering positive in 
this screen may have had allosteric effects on regions of Raf not directly interacting 
with Ras.  
To add another layer of complexity to the potential mechanism of action 
(MOA) of MCP110 and related compounds, as well as to experimental approaches 
to identifying inhibitors of Ras-Raf and to testing and validating inhibitor MOA, the 
activation of Raf-1 involves a series of steps involving membrane translocation, 
dephosphorylation at negative regulatory sites, and subsequent phosphorylation at 
activating sites in the kinase domain (Kolch, 2000).  Activation of B-Raf is similar but 
not identical, and currently there is much attention being paid to possible influences 
of Raf-1 on B-Raf and vice versa (Marais et al., 1997; Rajakulendran et al., 2009; 
Trakul et al., 2005; Wellbrock et al., 2004).  Given that localization of Ras and the 
complex regulation of Raf are key determinants for activation of the signaling 
cascade, it is also possible that the original screen could have selected lead 
candidates affecting Ras or Raf interaction with other proteins that are positive 
regulators of the pathway. Several scaffolding proteins interact with members of the 
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Ras-Raf-MAPK pathway to regulate the pathway by effects on protein localization or 
protein-protein interactions (Kolch, 2005).  For example, Sur-8 is an evolutionarily 
conserved scaffold protein that is a positive regulator required for optimal Ras-MAPK 
signaling (Sieburth et al., 1998).  Sur-8 facilitates Ras-Raf complex formation (Li et 
al., 2000), whereas reduction of Sur-8 suppresses activated Ras-mediated signaling 
in C. elegans (Li et al., 2000; Sieburth et al., 1998). The formation of a ternary 
complex of Sur-8 with activated Ras and Raf suggests that Sur-8 could also be a 
potential target of MCP110 activity, although the ability of MCP110 to impair the 
interaction of Ras with just the Raf-RBD interaction indicates that Sur-8 would not be 
an exclusive target.   
 An important finding of this study was therefore our detection of MCP110-
mediated disruption of the physical Ras-Raf interaction, providing evidence for the 
first time that MCP110 significantly disrupts the protein-protein interface involving 
full-length H-Ras and the Raf-RBD in mammalian cells.  This indicates that MCP110 
can act as a true protein-protein interaction inhibitor.  Whether it also disrupts the 
interaction of K-Ras and N-Ras with Raf-RBD remains to be determined.  Also 
remaining to be determined is whether it shows selectivity for disruption of 
interactions of Ras with the different Raf isoforms.   
 The strong association of Raf-RBD with Ras-GTP versus Ras-GDP (Herrmann 
et al., 1995) supports MCP110 disruption of the Ras-Raf complex, but the selectivity 
of MCP110 to disrupt interactions between Ras and Raf versus other GTPase/RBD 
pairs has also not yet been determined. Given that it is presently unclear whether 
MCP110 binds to Ras, to Raf-RBD or both, it would also be of interest to evaluate 
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the ability of MCP110 to disrupt the interaction of the RBDs of other GTPases and 
their effectors.  For example, RBDs of Ral GEFs (RalGDS, Rgl1-3) can interact with 
Ras as well with the Rap1A GTPase (Esser et al., 1998; Spaargaren and Bischoff, 
1994; Wolthuis et al., 1996). Whether MCP110 can also disrupt the interaction of 
Ras with RalGEF RBDs or Rap1A with Raf-RBD will be important to determine.  
Additionally, the effector domain of the Ras-related GTPase Rit provides a similar 
surface to that of Ras (Fischer et al., 2007), and may thus also be disruptable by 
MCP110, MCP116 or related compounds.  Finally, why MCP110 and MCP116 did 
not display the same ability to inhibit the Muv phenotype induced by the C. elegans 
Raf ortholog LIN-45AA is currently unclear.  The availability of structural information 
on complexes of MCP110 and of MCP116 with Ras-Raf would be of great 
assistance in making predictions about the most fruitful avenues to pursue in these 
directions. 
 
CONCLUSIONS 
Here we used both mammalian cell culture studies and the genetically 
tractable C. elegans in vivo model to investigate the activity of putative Ras/Raf 
interaction inhibitors.  We dissected the pathway and were able to determine that 
MCP compounds act downstream of Ras/LET-60 and upstream or at the level of 
Raf/LIN-45, thereby providing additional proof-of-principle for the use of C. elegans 
as a simple and attractive model for the characterization of novel or already isolated 
Ras pathway inhibitors. The work presented here has contributed to a better 
understanding of the mechanism of action of putative Ras/Raf interaction inhibitors 
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based on the MCP110 pharmacophore. Besides supporting previous conclusions 
that MCP110 significantly inhibits the signals caused by activated Ras in vitro and in 
vivo, we have been able to narrow the requirements for its activity by successfully 
using it to disrupt the Ras/Raf-RBD interaction.  In future, MCP110 can be further 
analyzed to test its selectivity towards other Ras effectors harboring RBDs. Perhaps 
the existing MCP110 analog can be further improved to increase its potency and 
target selectivity for further testing in additional pre-clinical models. Moreover, it 
would be interesting to see if additional screens involving Ras and the Raf-RBD 
could be developed to isolate novel Ras/Raf interaction inhibitors. 
 
METHODS 
 
C. elegans strains, strain maintenance and culturing conditions 
Strain maintenance and nomenclature are as described (Brenner, 1974; 
Horvitz et al., 1979).  Expression of activated Ras was from the n1046 allele in which 
an in situ mutation in LET-60/Ras causes a G13E change equivalent to that in 
human Ras, which is functionally similar to the well known G12V activating mutation 
(Beitel et al., 1990).  For activated Raf, we used lin-45AA (kuIs57) (Yoder et al., 
2004).  Activation of Raf is a multistep process in which several regulatory residues 
are modified to regulate its kinase activity. Transgenic alteration of the conserved 
Akt negative regulatory sites from serine to alanine at residues 312 and 453 (“AA”) in 
Raf leads to a hyper-induced phenotype comparable to that conferred by activated 
Ras (Chong et al., 2001; Yoder et al., 2004). Activated MEK/ERK resulted from 
transgenic expression of both activated Drosophila MEK (MEK-2) and activated C. 
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elegans ERK (MPK-1), all driven by a heat-shock promoter (gaIs37 (Lackner and 
Kim, 1998)). Consequently, the MEK/ERK Muv phenotype is temperature-sensitive, 
such that animals are grown at 25˚C to induce a Muv phenotype, but are wild type at 
15˚C (Lackner and Kim, 1998). Finally, as used herein, “Ets” refers to loss of the 
LIN-1/Ets transcription factor function (lin-1 null (sy254)). LIN-1 inhibits vulval fate, 
so LIN-1 loss results in hyper-induction (Beitel et al., 1995; Lackner and Kim, 1998). 
Strains were cultured on 2% NG agar plates seeded with E. coli strain OP50. The 
SD418 gaIs37 (mek-2(gf)+mpk-1(gf)) strain was maintained at 15°C and switched to 
25°C to induce its conditional hyper-induced phenotype. 
 
Drug assays  and quantification of  the multivulva (Muv) phenotype 
The experimental procedures for C. elegans drug treatments and phenotype 
quantification were previously described in detail (Reiner et al., 2008). Briefly, 
experiments were performed in 6-well tissue culture plates in which only the four 
corner wells were filled with 3 ml of 2% NG agar. Either vehicle (dimethyl sulfoxide; 
DMSO) or experimental drug (MCP110, MCP116, or MCP146) was diluted in M9 
buffer and applied in a defined volume to the agar in each well to achieve the final 
dose. Plates absorbed the drug overnight, then were seeded with 90 µl of OP50 
overnight culture and allowed to grow for 24 hours to ensure a suitable bacterial 
lawn.  
To obtain a population of treated animals that was developmentally 
synchronous, we harvested embryos during a narrow time frame. For each strain 
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and drug, 12-15 adult hermaphrodites laid eggs for 3 hours, after which the parents 
were removed.  
Animals to be assayed were exposed to drug throughout development. let-
60(gf), kuIs57 and gaIs37 animals were scored as early adults using the dissecting 
microscope.  lin-1(sy254) vulval invaginations were scored at the 4th larval stage (L4) 
because adult pseudovulvae were too distorted to quantify clearly (Reiner et al., 
2008). For DIC microscopy, lin-1 animals were mounted on slides in M9 buffer 
containing 5 mM sodium azide. 
To reproducibly score the outcome of drug assays, we used a specific set of 
phenotypic criteria. First, we categorized animals in a binary assay as Muv or non-
Muv, depending on the presence of the ectopic pseudovulvae that indicate hyper-
induction of vulval tissue. Second, we quantified the number of ectopic 
pseudovulvae. Each genotype assayed had a different baseline for degree of hyper-
induction, and therefore for each genotype the baseline was re-established such that 
animals treated with the experimental drug were normalized to the level of hyper-
induction in animals treated with vehicle. 
 
Statistical analyses 
Two-way ANOVA interaction analyses were performed to characterize the 
effect of each drug at each concentration on each treated strain.  A p value of < 0.05 
was considered significant.  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Cell culture and transfections 
NIH3T3 mouse fibroblasts were grown in DMEM (Sigma-Aldrich) 
supplemented with 10% GCS calf serum (Gibco) and 1% penicillin/streptomycin 
(Gibco) and maintained in 5% CO2 at 37°C.  Cells were plated the day before 
transfection at a density of 200,000 cells per 60 mm dish or 100,000 cells per 35 mm 
dish (or in a 6-well plate), for the pulldown and co-localization assays, respectively. 
For pulldown assays, pCDNA3.1 (vector only, v.o.) or pCDNA3.1 encoding activated 
H-Ras(12V) were transfected transiently into cells using TransIT-LT1 Transfection 
reagent (Mirus) according to the manufacturer’s specifications. For co-localization 
assays, pEYFP-Raf-RBD was cotransfected with either empty pCGN-HA vector 
(v.o.) or pCGN-HA encoding activated H-Ras(12V).  Immediately after transfection, a 
designated amount of either DMSO vehicle or MCP110, MCP116 or MCP146 was 
added at 3, 10 or 30 µM and further assays were performed after 48 h. 
 
Pulldown assays and immunoblotting 
 Transiently transfected NIH3T3 cells (see above) were lysed in 400 µl of 
freshly prepared Magnesium Lysis Buffer (MLB) combined with protease inhibitors 
cocktail (BD BaculoGold, BD Biosciences Pharmingen). Lysates were cleared by 
centrifugation at 12,000 RPM for 10 minutes at 4°C, and protein concentration was 
measured in a Bradford Assay (Bio-Rad laboratories, Hercules, CA). GST fusion 
proteins of the Raf-1 Ras binding domain (GST-Raf-RBD) were prepared from 
pGEX2T encoding Raf-RBD as described previously (Smith and Johnson, 1988; 
Taylor and Shalloway, 1996). Empty vector pGEX2T plasmid encoding GST alone 
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was a negative control.  A total of 100 µg of MCP110 pre-treated protein lysate was 
incubated with 10 µl of glutathione agarose beads (Sigma) previously coupled to 
GST alone or to GST-Raf-RBD. Parallel with the implementation of the lysate and 
the bead fusions, additional drug was added and the pulldown reaction was 
performed in a final volume of 500 µL, rocking for 1 h at 4°C. Protein bound to beads 
were collected, washed three times in lysis buffer and eluted in non-reducing protein 
sample buffer. Pulldown samples and total protein were analyzed by SDS-
polyacrylamide gel electrophoresis and western blotting. 
For immunoblotting, membranes were blocked in 5% non-fat dry milk and 
incubated overnight with primary antibodies diluted to 1:3,000 for H-Ras, 1:500 for p-
ERK (Cell Signalling) or 1:2,000 total ERK (Cell Signalling) dilution, overnight at 4°C. 
Membranes were washed and incubated for 1 h in a 1:30,000 dilution of anti-mouse 
or anti-rabbit IgG-horseradish peroxidase antibody (Amersham), washed extensively 
with TBS-T and developed with SuperSignal West Dura Extended Duration 
substrate (Thermo Scientific, Rockford, IL). 
 
Inmunofluorescence for recruitment of Raf-RBD probe 
NIH 3T3 cells were grown on coverslips, transiently transfected as above, and 
treated with MCP110 for 48 h before fixation in 3.7% formaldehyde, permeabilization 
with 0.5%Triton and blocking in 2% BSA for 1 h at room temperature. Coverslips 
carrying fixed cells were incubated in a 1:200 dilution of anti-HA antibody (Covance) 
for 1 h, followed by two washes in 1X Phosphate Buffered Saline (PBS), an 
additional incubation with AlexaFluor594 anti-mouse conjugated secondary antibody 
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(Invitrogen, 1:1,000) for 30 min and washed three times with 1X PBS. Coverslips 
were mounted into a glass microslide with ProLong Gold antifade mounting medium 
and cells were visualized by confocal microscopy. 
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Figure 3.1 MCP110 and MCP116 but not MCP146 inhibit the Ras/LET-60-
induced Muv phenotype.  A.  Representative images of:  left, untreated wild-type 
animals; center, progeny of animals harboring constitutively activated Ras treated 
with vehicle only (Muv phenotype; ventral protrusions from pseudovulvae); right, 
progeny of the same worm strain shown in the center panel, following treatment of 
parents with 20 µM of MCP110 (reversal of Muv to WT, as indicated by lack of 
ventral protrusions). B. Animals harboring constitutively activated Ras as in panel A 
were treated with either vehicle (DMSO) or MCP110, MCP116 or MCP146 (3, 10 or 
20 µM; higher concentrations precipitated out of solution). The Y-axis indicates the 
percentage of treated animals with hyper-induced Muv phenotype, normalized to the 
number of vehicle-treated animals with Muv phenotype. Data were analyzed by two-
way ANOVA.  (**) indicates a p value of less than 0.0001. 
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Figure 3.2. MCP110 and derivatives do not inhibit the Muv phenotype induced 
in worm strains harboring mutations in components of the Ras-Raf-MAPK 
pathway downstream of Raf.  Animals were treated and results shown as for 
Figure 1B:  A. Ets and B. activated MEK/ERK. 
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Figure 3.3. MCP110 inhibits the Muv phenotype of worms expressing activated 
Raf/LIN-45. kuIs57 (lin-45AA) transgenic animals expressing a constitutively 
activated Raf/LIN-45 protein were treated with 3, 10 or 20 µM doses of vehicle 
(DMSO) or MCP110. The Y-axis indicates the percentage of treated animals with 
hyper-induced Muv phenotype, normalized to the number of vehicle-treated animals 
with Muv phenotype. Data were analyzed by teo-way ANOVA. animals. (**) indicates 
a p-value of  <o.0001 and (*) denotes a p≤0.01.) 
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Figure 3.4. MCP110 inhibits Ras/Raf interaction in mammalian cells. A.   
Pulldown assay for Ras-Raf interaction.  Pulldowns of active H-Ras(12V) were done 
using GST-Raf-RBD as described in METHODS. NIH 3T3 cells and subsequent 
lysates were treated with vehicle or MCP110 (3, 10 and 30 µM). Ras was detected 
by immunoblotting with a specific H-Ras antibody. Both Raf-RBD-bound Ras (upper 
panel) and total Ras in the lysates (lower panels) are shown.  MCP110 disrupted the 
Ras/Raf interaction in a dose-dependent manner; numbers shown indicate 
quantitation of Ras pulldown by densitometry, normalized to vehicle control.   B. 
Western blot analysis for phospho-ERK.  The same lysates from cells expressing 
active H-Ras(12V) depicted in panel A above were immunoblotted for phospho-
ERK1/2(S473) (upper panel) and for total ERK1/2 (lower panel) and quantitated by 
densitometry.  MCP110 decreased ERK activation in a dose-dependent manner.  C. 
Immunofluorescence localization of YFP-Raf-RBD probe for active Ras-GTP.  
NIH3T3 cells transiently expressing H-Ras12V and YFP-Raf-RBD were treated with 
vehicle or MCP110.  Representative images of cells quantitated in Panel D below 
are shown here.  In the absence of active Ras (v.o.), YFP-Raf-RBD was localized 
diffusely throughout the cytoplasm and nucleus, whereas in the presence of active 
Ras (H-Ras(12V)), the Raf-RBD probe was recruited to the plasma membrane and, 
like Ras, was nuclear-excluded (vehicle panels). Increasing concentrations of 
MCP110 increasingly shifted the YFP-Raf-RBD probe from the plasma membrane to 
the cytosol and to internal membranes and finally to both cytosol and nucleus, 
whereas Ras remained membrane-associated and nuclear-excluded, indicating 
dose-dependent disruption of the Ras/Raf-RBD interaction.   D.  Quantification of the 
distribution of YFP-Raf-RBD subcellular localization.  Cells were binned according to 
whether the YFP-Raf-RBD probe accumulated primarily in the cytosol, or cytosol + 
internal membranes, or plasma membrane and was nuclear-excluded, as described 
in Methods and depicted qualitatively in panel C. 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
SUMMARY 
 
Through the progress of this work we have learned valuable lessons about the 
activity of MCP compounds as putative Ras/Raf interaction inhibitors. We first 
validated the Muv phenotype that results from Ras-, Raf- or MEK-driven 
hyperinduction of vulval development in C. elegans as an in vivo readout to assess 
the potency and selectivity of pharmacological inhibitors targeting the 
Ras>Raf>MEK>ERK pathway, thus providing a stronger base for its further use to 
evaluate other such inhibitors.   
Second, we evaluated the activity of putative Ras/Raf interaction inhibitors of the 
MCP class by taking advantage of a collection of worm strains harboring mutations 
at different levels of the Ras>Raf>MEK>ERK pathway (Table 2.1). Our results 
revealed the selectivity of MCP compounds inhibition of the Muv phenotype 
conferred by activating mutations at specific different levels of the pathway, and as a 
result of performing the assays in the genetically tractable worm model we were able 
to confirm that MCP acts downstream of Ras and upstream or at the level of Raf. 
Complementary results were obtained when testing the ability of MCP110 to 
interrupt Ras/Raf interaction in pulldown assays. This approach allowed us to show 
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for the first time that this putative Ras/Raf interaction inhibitor is really capable of 
physically disrupting the interaction between activated Ras and Raf in mammalian 
cells.  Further, we narrowed down the site of interaction to Ras and the Raf-RBD.  In 
these cells, we also were able to demonstrate impaired recruitment of Raf-RBD to 
sites of membrane-bound, active Ras.  Although the mechanism of action of MCP 
compounds is still not completely known, in part because we do not know definitively 
if they bind to the Ras or Raf side of the interface, the weight of evidence suggests 
that they interact preferentially with Ras. 
 In addition to validating tools for the in vivo evaluation of known or novel 
inhibitors of the Ras>Raf>MEK>ERK signaling pathway, our studies support the idea 
that protein-protein interaction inhibitors of Ras/Raf interactions could target the 
pathway more effectively than FTIs or kinase inhibitors as discussed in the 
Introduction chapter, although this remains to be tested directly in the same system.  
Optimistically, in the near future there may be additional efforts to perform other 
screenings to look for novel protein-protein interaction inhibitors of Ras and Raf. For 
the last seven years, MCP compounds have undergone in vitro and in vivo 
evaluation. During this time these putative Ras/Raf interaction inhibitors have been 
of value in the laboratory for the inhibition of Ras-driven transformation in cells and 
the vulva formation in the worm. While the MCP110 compound itself, with its low-to-
middling micromolar activity in cell-based assays and real but modest activity in 
nude mouse xenografts, will not become a successful clinical candidate, it, like many 
other failed clinical candidates including the MEK inhibitor U0126, will likely continue 
to be very useful to inhibit existing or novel Ras-dependent assays in the laboratory.  
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Perhaps efforts to chemically modify the MCP pharmacophore to improve its 
selectivity and potency may lead to better Ras/Raf interaction inhibitors from the 
family of MCP compounds.  
As mentioned in the introduction to this dissertation, one of the advantages of 
using the worm as a model is the possibility to uncover compound-related off-target 
activity.  In testing the activity of MCP110 and related derivatives against Ras 
signaling, we identified an unexpected, dose- and compound-dependent phenotype, 
indicative of potential off-target activity.  This finding will be discussed on Future 
Direction 2. 
 My studies confirmed that the worm is not an ultimate model to fit all the 
needs for drug discovery strategies, but it can certainly be exploited as a model for 
disease-related pathways of interest that are highly conserved and in which 
functional readouts can be generated to measure their activity and the effects 
caused by inhibition of the pathway.  In the following sections I will describe three 
future directions that represent natural outgrowths of the work that I have 
accomplished while pursuing the research directions described in this dissertation. 
    
FUTURE DIRECTION I: Determine whether MCP110 interacts with the Ras or Raf 
interface 
 
In worms 
The analysis of MCP activity in let-60(gf), lin-45AA(gf), mek-2(gf) + mpk-1(gf) and 
lin-1(null) strains allowed me to test the selectivity of MCP towards the 
Ras>Raf><MEK>ERK pathway, but did not clarify whether MCP interacts with Ras 
or Raf to exert its anti-Muv activity. For that purpose, additional tools are required to 
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completely understand the mechanism of action of these compounds. I therefore 
attempted several strategies to generate new transgenic worms. Since we would like 
to determine if these small molecules are binding to Ras, to Raf, or to the Ras/Raf 
interface, it would be logical to test their activity in the absence of one or the other. 
This idea is based on several points – 1) the nature of the original MCP screen, in 
which a yeast-two hybrid assay was modified to select compounds that disrupt Ras 
interactions with Raf (Kato et al., 1992; Khazak et al., 2005), 2) the fact that the 
Raf/LIN-45AA mutant that is sufficient to induce a Muv phenotype, and that has 
been reported to be Ras-independent by virtue of S>A mutations at the Akt inhibitory 
sites, retains the RBD and may still depend on additional input from endogenous 
Ras, and 3) the fact that one of many critical steps for Raf activation is for the RBD 
in the N-terminus of Raf to make contact with the Ras effector domain, in part to 
promote phosphorylation that relieves autoinhibitory constraints on the kinase 
domain  (Figure 1.7 )(Leevers et al., 1994; Vojtek et al., 1993). Thus, our hypothesis 
is that the absence of a functional Ras binding domain in the otherwise constitutively 
active form of Raf/LIN-45AA or a similar construct would generate a truly Ras-
independent form of Raf, and this would be (unlike LIN-45AA) insensitive to MCP 
inhibition.   
 As a result, we embarked on the generation of a new transgenic animal 
expressing a constitutively activated LIN-45, lacking the RBD whose activity would 
be independent of Ras interaction. In order to generate a construct with those 
specifications, many considerations were taken into account.  First, as mentioned, 
Raf activation is complex and requires particular regions of the N-terminus (Figure 
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1.7). For that reason, I performed detailed sequence and computer-modulated 
secondary protein structure analysis to carefully select regions of LIN-45 that would 
be biologically functional, and then amplified by PCR the selected areas of LIN-45 
including the kinase domain and the complete C-terminal region of Raf (Figure 4.1). 
Additional sequences upstream of the kinase domain were added to ensure the 
proper conformation of the protein product of Raf/LIN-45.  
 Our first idea, was to target the LIN-45 kinase domain to the plasma 
membrane by adding the plasma membrane targeting sequence from Ras/LET-60, 
as similarly described in (Leevers et al., 1994). Given that human Ras variants have 
different hypervariable regions and CAAX motifs, the sequences of H-, N-, K- Ras 
and LET-60 were aligned and carefully analyzed, to reveal that the K-Ras 
hypervariable domain had the higher identity with LET-60 (Figure 4.1, blue). The 
LIN-45/LET-60 fusion constructs were made to express a fusion of LIN-45 kinase 
domain plus the hypervariable domain and the “CAAX”-related plasma membrane 
targeting sequence of LET-60 (Figure 4.1, yellow). However, many attempts to 
generate transgenic worms expressing this construct produced a high success rate 
of transgenics expressing the co-injection markers, but none showing the expected 
Muv phenotype indicative of expression of activated LIN-45-CAAX.  It is possible 
that overactivation of LIN-45 may cause toxic effects in embryos and thus not allow 
the viability of such LIN-45-CAAX transgenics. It is also possible that, regardless of 
the sequence homology between mammalian and worm genes, this strategy, which 
was previously performed in a mammalian system (Leevers et al., 1994), is not 
functional for the worm protein counterparts. 
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 A second strategy to generate a Ras-independent, LIN-45 activated construct 
was designed to once again amplify the kinase domain region of LIN-45, but without 
the LET-60 plasma membrane targeting sequence. This strategy was based on 
reports in which truncation solely of the first 305 amino acids from the N-terminal 
region of Raf (Δ22W) was sufficient to obtain a constitutively activated gene product 
that displayed high transforming activity in NIH 3T3 cells (Stanton et al., 1989) 
(Oldham et al., 1996). Given the high conservation of the kinase domain between 
mammalian Raf and LIN-45 (Figure 4.2C), we hypothesized that a similar construct 
would also be functional when expressed in the worm. However, in control cell 
culture experiments we did not observe expression of the protein product of several 
versions of this mutant, perhaps due to issues with protein stability. Therefore one 
important future direction is to address other approaches to the generation of a 
transgenic worm expressing constitutively activated but Ras-independent LIN-45, 
which does not presently exist.  In theory such a reagent would provide us with an 
excellent tool for the analysis of substrate requirements for MCP action.  However, 
because we were later able to obtain data in mammalian cells on MCP110-mediated 
disruption of the Ras/Raf interaction, future studies specifically on the mechanism of 
action of MCP compounds would be better done in that system rather than in C. 
elegans.   
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B. 
C.
Figure 4.1 Raf protein sequence alignments 
A) Protein sequence alignment of full-length human A-Raf, B-Raf, c-Raf and LIN-45. 
Also shown are alignments of B) ras-binding domains (Raf-RBD) [blue] and C) 
kinase domains [green]. Sequence alignments were performed in ClustalW2 
software (http://www.ebi.ac.uk/Tools/clustalw2/index.html).  As in Figure 1.4, (*) = 
identical, (:) = conserved substitutions and (.) = semi-conserved substitutions. 
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In mammals 
 Our results upon testing the ability of MCP110 to inhibit the Ras/Raf-RBD 
interaction brought us a step closer to elucidate the protein interface requirements 
for the activity of the drug. Now that we have evidence that MCP110 can disrupt the 
interaction between Ras and Raf-RBD, the rising questions are:  Does MCP110 also 
inhibit other Ras interaction with other effector pathways or is it specific for the 
Ras/Raf interaction in particular? Does MCP110 also disrupt the interaction of 
related small GTPases with the RBDs of their respective effectors?   
 To address the first question it would be necessary to assess the activation of 
other Ras downstream effector pathways in the same total lysate where Ras/Raf-
RBD interaction is disrupted by MCP110. For example another key directly 
interacting effector of Ras is the lipid kinase, PI3-K, that causes phosphorylation of 
its own indirect downstream target, the serine/threonine kinase, Akt (also known as 
PKB, protein kinase B). The observation of steady levels of Akt phosphorylation with 
concomitant reduced levels of ERK phosphorylation upon MCP110 treatment would 
be indicative that the disruption of Ras and Raf-RBD interactions is accomplished in 
a manner as to lead only to effects in the Raf>MEK>ERK pathway and not to other 
Ras effector pathways.  If seen, this might be more consistent with binding of 
MCP110 to Raf rather than to Ras, given the overlap in binding sites on Ras for 
PI3K (p85 subunit) versus for Raf.  Alternatively, while we assume that MCP110 is 
dispersed uniformly throughout the cell and would therefore not be subject to 
localization effects, one way to rule this out would be to dye-label the inhibitor and 
monitor its subcellular localization in treated cells. 
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 An alternative to discern the specificity of MCP110 towards disrupting the 
Ras/Raf-RBD complex, versus other related GTPases and their respective effector 
RBDs, would be to measure the ability of MCP110 to disrupt those interactions 
through pulldown assays. For example, it is known that the RBDs of Ral GEFs 
(RalGDS, Rgl1-3) can interact with Raf as well as with the Rap1A GTPase (Esser et 
al., 1998; Spaargaren and Bischoff, 1994; Wolthuis et al., 1996). Thus, it would be 
interesting to compare the ability of each of these RBDs to assess MCP110-
mediated disruption of the interaction of Ras or Rap1A with Raf- or Rgl-RBD. These 
results could potentially help disclose the selectivity of MCP110 for a certain 
GTPase (Ras vs. Rap or others) or to discriminate between effector binding RBDs. 
 
FUTURE DIRECTION II: Evaluate the specificity of MCP compounds at 
blocking only Ras/Raf interactions versus off-target activities 
 
Previous studies in cell-based assays have evaluated the ability of the MCP 
compounds to inhibit cell-autonomous phenotypes caused by Ras activation, but the 
physiological effects of these compounds in an in vivo system were not determined 
previously. In selecting the worm as a model to characterize the activity of MCP 
compounds we already started the process to do so. Since the development and 
behavior of the worm is so well-characterized, any off-target effects causing lethality, 
arrested development, slow growth, paralysis or behavioral changes can not only be 
easily detected, but the abundant literature and thoroughly curated databases such 
as “Wormbase” [http://www.wormbase.org] can also help us identify rapidly whether 
a certain phenotype has been previously observed and traced to a particular 
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pathway or protein. Another more laborious, but effective approach, as discussed in 
Chapter I, would be to perform a chemical genetic screen to phenotypically screen 
for any phenotypes resembling the ones caused by the drug and then proceed to 
genetically map the target gene. Of course, it is also possible that MCP compounds 
may have some off-target effects that cannot be readily observed under the 
dissecting microscope (low resolution), which may cause false negative conclusions.  
In the event, our results showed that, in addition to the ability of MCP 
compounds to selectively reverse the Muv phenotype of Ras and Raf but not 
MEK/ERK or Ets animals, they also caused changes in the social behavior of treated 
animals. Both wild type worms and animals mutant or transgenic for activation of the 
Ras>Raf>MEK>ERK pathway normally disperse and crawl randomly through the 
agar plates (Figure 4.2, left column); this “normal” behavior is often described as 
solitary behavior (de Bono and Bargmann, 1998). However, when exposed to 
MCP110 or MCP116, but not MCP146 or vehicle, Ras (let-60(gf), Ets (lin-1 null) and 
even wild type animals changed their solitary behavior and instead adopted a social 
behavior called “clumping” in which groups of worms congregated at the edges of 
the bacterial lawn (Figure 4.2). Moreover, the strength of this clumping behavior was 
dose-dependent (data not shown). This conglomeration of worms was easily 
disrupted by the movement of the plates, and also was restored after the plates were 
settled down for more than 20 minutes.  
The reproducibility of this conglomerating/social or clumping behavior 
suggests that MCP compounds are the source of this particular phenotype, since 
vehicle-treated worms behave normally and clumping is not dependent on the 
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genetic background of the strain being tested.  However, the clumping behavior can 
also be uncoupled from inhibition of the Muv phenotype in several ways.  First, 
MCP110 and MCP116 were equivalently potent at inhibiting Ras/LET-60-induced 
Muv (Figure 3.1), whereas MCP110 was significantly more potent at inducing 
clumping (Figure 4.2).  Second, MCP110 but not MCP116 induced clumping in LIN-
1-deficient worms (Figure 4.2), which have a Muv phenotype that is resistant to 
inhibition by either MCP compound (Figure 3.2).  Third, MCP116 induced some 
clumping in N2 wild type worms but not in LIN-1-deficient worms, the latter of which 
is Muv and the former of which is not.  Fourth, the MEK inhibitor U0126 robustly 
inhibits the Muv phenotype of animals expressinf Ras but has no effect whatsoever 
on clumping, indicating that clumping is not a necessary outcome of Muv inhibition. 
Together, these results indicate that MCP110 and MCP116 have two distinct 
activities, one of which is the intended inhibition of hyperinduced vulval formation 
(“on-target”) and the other of which is clumping behavior (“off-target”). 
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Figure 4.2. Off-target activity: changes in worm feeding behavior upon 
treatment with MCP compounds Treatment of Ras (let-60 gf), Ets (lin-1 null) or 
wild type (WT) strains with MCP110 and MCP116 caused a switch from normal 
solitary feeding behavior to social behavior (see red line).  MCP146 did not cause 
behavioral changes, suggesting that this is not simply a previously unappreciated 
effect of Ras/Raf inhibition but an off-target activity selectively present in MCP110 
and MCP116 but not MCP146.  
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This observation provides evidence that MCP compounds have alternate 
targets in addition to their activity towards inhibiting Ras/Raf interaction. This 
alternate activity was detected by the change in the feeding behavior of the animals 
treated with MCP compounds, but not DMSO vehicle.  Moreover, the strength of the 
aggregation/clumping phenotype was analog- and dose-dependent, since it was 
associated with only two analogs (MCP 110 and MCP116) and was seen only mildly 
at 10 µM and strongly at 20 µM. 
My colleague Dr. Reiner immediately recognized that this clumping behavior 
had been previously described in the literature (de Bono and Bargmann, 1998) as a 
natural variation of feeding behavior.  This behavior is associated with a variant of 
the orphan G-protein coupled receptor (GPCR), NPR-1. The wild type worms used 
here (N2) and solitary strains found in nature have a valine at residue 215, while 
naturally occurring social strains have a phenyalanine at this same position.  NPR-1 
encodes a predicted G-protein coupled receptor similar to neuropeptide Y receptors 
(NPYR) in humans (de Bono and Bargmann, 1998). In humans, NPYRs regulate 
food consumption, mood, anxiety, memory retention, hippocampal excitability and 
blood pressure (Blomqvist and Herzog, 1997).  Given the nature of our results, its 
possible that treatment with MCP-110 and MCP-116 may also be targeting the 
function of NPR-1, thus inducing the social/clumping behavior. Further testing of the 
ability of MCP110 and MCP116 to promote this behavior will require further 
behavioral assays using npr-1 mutants. These assays may reveal the potential of 
MCP compounds to inhibit the GPCR, and the possibility to create new 
pharmacological agents that retain only anti-NPR-1 activity. Currently, the MCP-
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driven clumping behavior is being evaluated by our collaborator Mario deBono 
(MRC, Cambridge, UK), who has expertise in the study of the npr-1 phenotype (de 
Bono and Bargmann, 1998). 
 
In summary, testing the activity of MCP compounds in C. elegans allowed the 
identification of an unexpected off-target effect that remains to be characterized.  
Altogether, our results support the idea that MCP 110 and MCP 116 may contain at 
least two different activities; 1) inhibition of Ras/Raf interaction and 2) inhibition of 
NPR-1. Our results also confirm the selectivity of this off-target activity, and show 
clearly that it can be uncoupled from the activity of inhibiting Ras/Raf interaction and 
from the strain being tested.  Moreover, our evaluation of the MEK inhibitor U0126 
supports the idea that disruption of the Muv phenotype is not sufficient to cause the 
switch to social behavior, confirming that these activities are separable and not 
simply nonspecific.   
 
 
FUTURE DIRECTION III:  Development of a novel screen for Rac pathway 
inhibitors - proof-of-principle using the Rac inhibitor EHT 1864 
 
Given the experiences I have gained in evaluating inhibitors of the 
Ras>Raf>MEK>ERK pathway, the thought of developing alternate strategies to use 
C. elegans as a model for other drug discovery efforts seemed reasonable. The 
selection of the next target for investigation included evaluation of the current 
literature to identify proteins that are both currently validated as potential targets for 
anti-cancer therapy and conserved in the worm. Our interest in small GTPases 
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quickly narrowed the number of attractive targets and we selected the small 
GTPase, Rac. 
 
BACKGROUND 
Rac belongs to the family of Rho (Ras homologous) proteins, a subfamily of 
the Ras superfamily of small GTPases (Ellenbroek and Collard, 2007).   (Figure 1.1).  
Rho small GTPases are regulated in a similar way to the Ras family of GTPases, 
where positive regulators including GEFs and negative regulators including GAPs 
control the “on” and “off” state of these proteins by modulating their GTP/GDP 
binding status.  In addition, Rho proteins are also regulated by a third class of 
modulators, Rho guanine nucleotide dissociators (RhoGDIs).  These ubiquitously 
expressed chaperone proteins have the capacity to retain most COOH-terminally 
processed Rho proteins (e.g., Cdc-42, Rac1, Rac2 and RhoA but not RhoB or TC10 
in the cytosol (Michaelson et al., 2001). The action of RhoGDI as a  negative 
regulator prevents the localization of Rho proteins to their targeted membranes, 
thereby preventing their full activation and interaction with downstream effectors until 
release of RhoGDI. The best characterized members of the Rho subfamily are 
RhoA, Rac1 and Cdc42, and their best known role is to regulate actin dynamics 
(Ellenbroek and Collard, 2007). In particular activation of Rho GTPases by 
extracellular stimuli or by introducing activated Rho proteins causes the formation of 
cellular stress fibers, lamellipodia and filopodia, respectively (Hall, 1998; Nobes and 
Hall, 1999).  In turn these changes in the actin structure also affect regulation of cell 
shape, cell adhesion and cell migration (Ridley and Hall, 1992a; Ridley and Hall, 
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1992b).  The specific regulation of lamellipodia by Rac therefore provides a selective 
for activation or inhibition of Rac function. 
  
 
RAC PATHWAY ACTIVATION IN TUMORIGENESIS 
 
To date activating mutations have not been detected in Rho family proteins; 
however, aberrant signaling is frequently accomplished by alterations affecting their 
regulators (as summarized in Figure 4.3). For example the increased expression of a 
Rac-specific positive regulator, the GEF Tiam-1 (Mertens et al., 2003), has been 
correlated with the progression of renal cell carcinoma, prostate and breast cancer 
(Adam et al., 2001; Engers et al., 2006; Engers et al., 2000; Minard et al., 2004). 
Moreover, there is additional in vivo evidence showing that mice deficient in Tiam1 
are resistant to Ras-induced tumors (Malliri et al., 2002), indicating that this RacGEF 
is required for full oncogenesis.  Also, the loss of expression of a Rho GAP, DLC-1 
or Rac-GAP β-chimaerin, leads to persistent activation of Rho GTPases in liver 
cancer (Ching et al., 2003; Yuan et al., 1998) and in breast cancer, respectively 
(Yang et al., 2005). In addition to the deregulation of Rac modulators, Rac itself is 
also overexpressed in a subset of cancers; among these are included gastric cancer 
(Pan et al., 2004), testicular cancer (Kamai et al., 2004), breast cancer (Fritz et al., 
2002), oral squamous cell carcinoma (Liu et al., 2004) and brain cancer (Hwang et 
al., 2005a; Hwang et al., 2005b). The deregulation of proteins that modulate Rac 
activation or the overexpression of Rac in various types of cancers provides 
substantial evidence that Rac is important for the onset and maintenance of cancer.  
Also, our laboratory showed that Rac1 and Rac3 are physiologically relevant targets 
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of the anti-transforming activity of geranylgeranyltransferase inhibitors (Joyce and 
Cox, 2003).  Altogether the deregulation of several elements of Rac pathways in 
different types of cancer and the relevance of key regulators like Tiam1 for 
tumorigenesis begins to validate Rac as a good target for the development of new 
anti-cancer therapies.  Additional direct validation comes from recent work showing 
that mice deficient in Rac1 are impaired in Ras-mediated lung cancer formation 
(Kissil et al., 2007). 
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Figure 4.3.  Rac activity is deregulated in many cancers. Rac itself does not 
harbor activating mutations; on the other hand deregulation of Rac caused by over 
expression of RacGEFs (e.g., Tiam1), decreased expression of GAPs (e.g., b-
chimaerin) or overexpression of Rac itself has been reported for subsets of cancers. 
 
 
 
   137 
RAC PATHWAY AS A TARGET FOR ANTI-CANCER DRUGS 
One example of a promising Rac-specific inhibitor is EHT1864.  Although the 
exact mechanism of action of EHT1864 is not yet understood, it is thought to act in 
an unusual manner by displacing guanine nucleotide from Rac, thereby allowing it to 
block both wild type and active Rac.  Consistent with this, EHT1864 has been 
validated in cell-based assays to inhibit the lamellipodia formation caused by PDGF-
mediated stimulation of wild type Rac (Shutes et al., 2007) and the transformed 
phenotype caused by activating mutations in Rac (e.g., G12V) or Tiam1 (Desire et 
al., 2005).  Whether EHT1864 has activity in vivo is not known.  
 The p21-activated kinases (PAKs) are also attractive targets for anticancer 
drug development against the Rac pathway. PAKs are a highly conserved family of 
serine/threonine kinases with six human members, PAK 1-6, that serve as 
downstream effector proteins for Rac and related Rho family GTPases.  Only PAK1-
3 bind active Rac, whereas all of them can bind Cdc42 (Ellenbroek and Collard, 
2007). Existing evidence supports PAK as an essential mediator for cell 
transformation caused by oncogenes like Ras. Moreover, there is evidence that 
PAK1 is also upregulated in breast cancers (Salh et al., 2002; Vadlamudi et al., 
2000) and that other PAK family members are also associated with other tumor 
types. A detailed review of the biological role of PAK family members and their 
association with different types of cancer is provided elsewhere (Kumar et al., 2006). 
Previous evidence supports that overexpression of mutationally activated PAK is 
sufficient for mammary gland tumor formation in mice (Wang et al., 2006). Moreover, 
there is additional evidence that kinase-deficient PAK mutants inhibit cell 
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transformation mediated by the Ras-Rac pathway (Tang et al., 1997). Altogether 
these results highlight PAK as a potential target for anticancer therapies. To date 
there are several compounds that inhibit PAK activity by targeting either its kinase 
activity or its interaction with other proteins (reviewed in (Kumar et al., 2006)).  In 
summary, there are considerable in vitro and in vivo data showing the efficacy of 
inhibitors targeting either Rac activity or the activity of one of its downstream 
effectors, PAK. The existence of such inhibitors is not discouragement to keep 
searching for additional and perhaps better Rac pathway inhibitors. 
 
RAC PATHWAY IN C. ELEGANS 
 
C. elegans has two Rac1 homologs: CED-10 and RAC-2, which both have 
83% identity to the protein sequence of Rac1 (Lundquist et al., 2001). However, 
analysis of sequence alignments of the worm Rac variants and their human 
counterparts showed that CED-10 shares the most similarities with Rac1. Previous 
studies using RNAi or loss-of-function mutants demonstrated that CED-10 is 
necessary for distal tip cell migration, axon guidance and axon pathfinding and cell 
corpse phagocytosis (Lundquist et al., 2001). On the other hand, the expression of a 
gain-of-function ced-10(G12V) under the control of a neuron-specific unc-115 
promoter displayed premature CAN axon termination, misguidance and ectopic 
branching (Lundquist et al., 2001).  These results indicate the importance of CED-10 
to worm function. 
 In addition to the conservation of CED-10 itself, other regulatory proteins and 
downstream effectors of Rac are also conserved in the worm. For example the 
specific mammalian Rac GEF, Trio, is conserved in the worm.  Its counterpart, UNC-
   139 
73, functions through Rac to modulate cytoskeleton rearrangements (Hansson, 
1983). Another regulator of Rac1 also conserved in worms is RhoGDI. The 
molecular characterization of C. elegans RhoGDI (ceRhoGDI), showed that 
ceRhoGDI has affinity for all counterparts of the worm RhoGTPases (Yap et al., 
1999).  Also to date three homologs of the Rac downstream effector, PAK, have 
been found in the worm (Lucanic et al., 2006).  The conservation of these important 
elements of the Rac pathway in the worm highlights the potential to use C. elegans 
for the development of genetic in vivo tools for the screening of Rac pathway 
inhibitors.  
 
GENERATION OF RAC/CED-10-DEPENDENT LETHAL PHENOTYPE FOR DRUG 
SCREEN BINARY READOUT 
 
 Based on the homology of Rac with CED-10, there is potential to perform 
genetic manipulations in the worm to generate an in vivo system where worms 
carrying activated CED-10 can be used to screen for Rac pathway inhibitors.  The 
design of a powerful drug screen would involve the use of a phenotype that can be 
easily scored, where a dramatic and positive change occurs upon pathway inhibition, 
and preferably utilizes a simple binary readout such as dead vs. alive to reveal the 
activity of a candidate drug.  
 In a standard drug screen, wild-type animals would be treated and the 
endpoint would be to look for phenotypes reminiscent of genetic loss of function of 
CED-10. However, the phenotype of ced-10(lf) involves defects in cell corpse 
phagocytosis and axon pathfinding. These phenotypes are both weak and 
unconventional for the design of a high throughput screen, since scoring any of 
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these defects involves mounting animals on microscope slides and using DIC 
microscopy, which is very low throughput. Therefore, treatment of wild type animals 
with a Rac inhibitor would be expected to yield only incremental changes in these 
animals, making the screen complex, laborious and very low-throughput.   
Another approach to sensitize the pathway for the development of a drug 
screen is by using gain-of-function mutations. As described in Chapters II and III of 
this dissertation, the increased signaling and aberrant phenotype caused by an 
activating mutation in Ras/LET-60 can be reversed to normal signaling and wild type 
phenotype by treatment with inhibitors targeting downstream effectors of LET-60.  
The use of a similar gain-of-function mutation in Rac/CED-10, to cause increased 
signaling and a robust aberrant phenotype, could then be reversed to normal by 
inhibitors of the Rac1/CED-10 pathway (Figure 4.5).  A mutation from glutamine (Q) 
to leucine (L) in residue 61, located in the switch 2 region, leaves both Rac and 
CED-10 insensitive to negative regulation and constitutively active in mammals and 
worms, respectively. However, unlike Ras/LET-60, where a gain of function causes 
a hyper-induced Muv phenotype in adult worms, constitutive activation of Rac/CED-
10 causes embryonic lethality.  The expression pattern of CED-10 is located 
throughout the embryo early in development and at different specific cell types 
during the adult stages. CED-10 is a critical player in the migration of epithelial cells 
and is important to achieve the ventral enclosure of the embryo, which generates a 
structurally intact animal (Lundquist et al., 2001).   Enclosure of the embryo is a key 
step required to ensure that the embryo will reach the following developmental 
stage, which is elongation. Failure of these cells to migrate and enclose the embryo 
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therefore causes embryonic lethality. As a consequence, the overall expression of 
mutationally activated CED-10 results in catastrophic defects in the development of 
the worm, and transgenes could not be isolated.  
However, it is possible to take this natural event and use it to our advantage.  
The goal is to avoid the overall toxicity caused by constitutive overexpression of 
activated Rac/CED-10, yet permit normal development of parental worms followed 
consistently by embryonic lethality under defined conditions unless the Rac pathway 
is interrupted successfully, for example by a pharmacological inhibitor.  To achieve 
this goal, my collaborator, Dr. David Reiner (UNC-CH), devised and engineered a 
conditional expression system in which expression of activated CED-10 is driven by 
the epithelial-specific lin-26 promoter and so CED-10 is expressed only in epithelial 
cells.  In addition, the construct contains a 3’ UTR engineered to be sensitive to 
nonsense-mediated decay (NMD) mRNA decay. NMD normally works as a cellular 
mechanism of mRNA surveillance, to detect premature nonsense mutation and 
prevent the expression of truncated or aberrant proteins. 
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Figure 4.4  Overview of a positive binary readout for screening putative Rac 
pathway inhibitors. We generated a conditional system to allow expression of the 
otherwise embryonically lethal activated Rac/CED-10.  This conditional system 
allows rescue of lethality by inhibitors of activated Rac or of the Rac pathway. 
Survival versus lethality thus acts as a positive and binary readout to identify 
candidate Rac pathway inhibitors. 
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A transgenic animal containing this construct was generated in a 
temperature-sensitive mutant background that conditionally disrupts the NMD 
system. As a consequence, in animals grown at 15°C, NMD is active, and the CED-
10 transcript is degraded.  On the other hand, in animals grown at 23°C, NMD is 
inactive, and the CED-10 transcripts are stably expressed. This conditional 
expression system has allowed the isolation and maintenance at 15°C of what would 
otherwise be a toxic transgene. Also it allowed the generation of a binary readout, 
indicative of Rac-specific expression, where at 15°C worms are alive and at 23°C 
worms are dead. If, in a screen, a given compound rescues the ced-10-driven 
lethality, then it would be a potential candidate for a Rac pathway inhibitor. 
  A successful screen will also require 100% lethality in the absence of a Rac 
inhibitor.  Maintenance at 15°C ensures the conservation of this transgenic strain, 
but for experimental purposes I needed to determine the minimal temperature at 
which 100% lethality is reached. The relevance of finding this key temperature was 
to ensure that the lethal phenotype can be altered by minimal pharmacologic 
intervention.  To determine this basal temperature I grew ced-10(Q61L) animals at a 
range of temperatures and scored their viability and lethality proportions at each 
temperature (Figure 4.5).  This titration experiment allowed me to identify 23°C as 
the minimal temperature for 100% lethality, and was therefore selected as the 
screening temperature. 
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Figure 4.5  Temperature titration of Rac/CED-10-dependent lethal phenotype. 
The minimal temperature for 100% lethality of ced-10 gf transgenic animals was 
determined to be 23°C. 
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EVALUATE THE ABILITY OF A VALIDATED RAC INHIBITOR (EHT 1864) TO 
RESCUE THE LETHAL PHENOTYPE OF WORMS EXPRESSING ACTIVATED 
RAC/CED-10 
 
EHT 1864 has been evaluated and characterized as a putative Rac inhibitor. 
The published evidence has shown that this inhibitor has in vitro and in vivo activity 
(in cells) towards both wild type and activated Rac. In these studies, the authors 
successfully showed that this compound can reduce both the lamellipodia formation 
caused by PDGF-mediated stimulation of wild type Rac (Shutes et al., 2007) and the 
transformed phenotype caused by Tiam1 or by activating mutations in Rac(G12V) 
(Desire et al., 2005).  The mechanism of action of EHT 1864 is not well understood, 
but it is thought to act unconventionally, by displacing nucleotide from either active 
or wild type Rac.  If this inhibitor does work at the level of Rac or perhaps even 
downstream, then it should rescue the lethal phenotype caused by the expression of 
activated CED-10. However if it works by inhibiting upstream regulators (e.g., 
GEFs), then these inhibitors should not be expected to rescue the lethal phenotype 
of these animals, unless activated CED-10 lethality also requires wild type Rac. At 
the same time that we use this inhibitor to validate our system, we could also unveil 
new information that could help understand better the mechanism of action of 
EHT1864.  Given the nature of the proposed action of this Rac inhibitor, we 
expected to be able to validate our system by rescuing the CED-10-dependent lethal 
phenotype at 23°C in a dose-dependent manner.  
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Figure 4.6 EHT 1864 rescues the lethal phenotype of CED-10 transgenic 
worms. A) Visual representation of lethality rescue by EHT 1864 of ced-10(gf) 
animals grown at 23°C. B) EHT 1864 rescued the lethal phenotype of  CED-10 
transgenic worms in a dose dependent manner.  
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Treatment of CED-10 transgenic worms showed that EHT 1864 rescued the 
CED-10-dependent lethality in a dose-dependent manner.  The establishment of the 
system as a binary readout allowed the visual scoring of the positive effects of EHT 
1864 as shown in Figure 4.6A.  In addition to the visual scoring process, the number 
of worms surviving upon addition of EHT 1864, was quantified.  I detected nearly 
100% rescue at 30 µM EHT 1864 (Figure 4.6B). Additionally, worms were not only 
rescued from lethality, but many also progressed farther in development. For 
example, more worms advanced to the L1 stage when treated with EHT 1864 (data 
not shown). Additional experiments have shown that the rescue of CED-10-
dependent lethality is reproducible and dose-dependent. Control experiments to 
confirm the selectivity of EHT 1864 for inhibition of Rac compared to other highly 
related small GTPases showed that treatment of NIH 3T3 mouse fibroblast cells with 
this Rac inhibitor reversed induction of lamellipodia formed upon stimulation of wild-
type Rac by PDGF, but failed to reverse formation of stress fibers or filopodia, which 
are phenotypes caused by activation of Rho or Cdc42, respectively (data not 
shown).  These results are consistent with rescue of C. elegans lethality as a 
specific consequence of inhibiting Rac activity. 
 
The results obtained here validate the use of the CED-10-dependent lethal 
phenotype as the readout for the development of a screen for putative Rac pathway 
inhibitors. Rescue of the lethal phenotype was consistently reproducible and also 
strong. The ease with which the rescue of these animals can be detected supports 
the idea that this will be a viable and powerful way to screen for putative inhibitors of 
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Rac or the Rac pathway. By using this binary readout, the assay can be easily 
optimized to meet the requirements of a high throughput screen by using first 96-well 
plates and then 384-well plates in which thousands of compounds can be screened 
at once, under the dissecting microscope. In addition to validating this system for the 
development of a screen for Rac pathway inhibitors, our preliminary data opens the 
possibility of using this system to screen for inhibitors of other clinically relevant 
targets. In addition to detecting positive candidates, the use of an in vivo system 
would offer the advantage of detecting compounds with relevant biological activity 
and the ability to discard compounds with toxic properties earlier in the drug 
discovery process. 
 
 
Designing a HTS to pursue screening 
 
Given the positive validation of the CED-10-dependent lethal phenotype 
rescue by a Rac specific inhibitor (EHT 1864), we now have a system with which to 
design a screen for putative Rac pathway inhibitors. In such a screen, any 
compound that can rescue the lethal phenotype of worms with activated CED-10 
would be considered a potential candidate for a Rac specific or Rac pathway 
inhibitor. Moreover, the binary readout offered by this system will allow the visual 
screening of thousands of compounds simultaneously, that can be executed even by 
inexperienced researchers. 
 
Developing the HTS screen 
In order to develop the worm culture conditions to meet the requirements of a 
high-throughput screen, I will need to switch my current protocol from solid agar to 
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liquid culturing media. This can be achieved by adopting similar culture conditions 
often used for the construction of deletion mutant libraries to generate C. elegans 
gene knockouts (§).  Briefly, adult hermaphrodite worms are grown and 
synchronized using the bleaching protocol, described above in Chapter II. Newly 
hatched larvae are synchronously grown and titrated to control the amount of 
animals to be dispensed in each well of a 96-well plate. Performing these 
experiments in a 96-well plate would accelerate the screening process, making it a 
more powerful design by increasing the probabilities of screening more compounds 
per experiment and also finding positive candidate compounds. In my collaboration 
with the BRITE Institute (Biomanufacturing Research Institute and Technology 
Enterprise) at North Carolina Central University (NCCU, see below), we have 
discussed that 96-well plates are for piloting the screen, which when successful on a 
smaller scale will be transitioned to 384-well plates suitable for robotic handling.  The 
conditions necessary to treat and grow animals in the screen will need to be 
carefully designed to ensure the assay will be proficient for its length.  Each 
screening plate will include control (vehicle wells) and also 2-3 different 
concentrations of each compound in the library to be screened. As drug potency and 
solubility varies from compound to compound it will be necessary to test various 
concentrations simultaneously. This strategy will increase the probability of detecting 
activity.  Additional logistics of the experimental design will need to be further 
developed as the process proceeds.   
   
I expect that by screening a small molecule chemical library, I will be able to 
find compounds that could rescue the CED-10-dependent lethal phenotype. Also, I 
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expect some compounds to produce a strong rescue while others may show weak 
activity at rescuing the lethal phenotype of these worms. But regardless of the 
strength of the rescue, potential hit compounds can be selected for further testing. 
Given that this screen is based on worms expressing activated CED-10, I expect to 
detect inhibitors of either Rac itself or perhaps inhibitors of downstream elements. 
Some of these inhibitors can be kinase inhibitors, but this predisposition will depend 
on the nature of the chemical library being screened. 
 
 Another possibility is that the library tested does not contain any compounds 
capable of interfering in the pathway, or where that interference is linked either 
mechanistically or nonspecifically with toxicity that will prevent the rescue of the 
lethal phenotype.  Some toxicity issues can be addressed by running parallel 
experiments at the permissive temperature of 15°C.  If CED-10 transgenics show 
lower viability at this temperature, it could be an indication of the toxic effects of a 
particular compound.  If I do not get any hits at all, it may mean that the library being 
tested does not cover the appropriate type of chemical entities.   
In consultations with personnel from the drug discovery facilities at BRITE, 
there were suggestions about the optimization of our current experimental platform. 
As mentioned above, among these were to not only try to optimize the assay to a 
96-well format, but if possible to 384-well format, since the current robotics utilized to 
dispense the compounds from their libraries are capable of this throughput, thus 
making any platform adjustment to work easier.  Our current plan for the analysis of 
hits is to visually screen each well for the rescue of ced-10-driven lethality, and 
although this would realistically yield a throughput of approximately a 5,000 
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compounds per day, this readout would not yet fit the standards of a real high-
throughput setting. Therefore, we need to work on generating a fluorescent readout 
that automated machines would be able to read to automatically collect the data 
from the screen. This fluorescent readout would have to be thoughtfully engineered 
so that it quantifies the worms whose lethality has been rescued by a screened 
compound.  Based on the latter, a stage-specific developmental marker would be an 
option, in which only those worms reaching certain developmental stages due to 
rescue can express the fluorescent probe. 
 Our consultation sessions with the personnel at BRITE facilities are the 
beginning of a potential collaboration for the development of the Rac-inhibitor pilot 
screen transition into a HTS at BRITE. Their facilities possess all the equipment 
necessary to accommodate the needs of the screen, and moreover they have 
several small molecule compound libraries that could be used as the starting point to 
initiate the screen, initially for proof-of-principle and later for true searching.   We 
foresee that the development of this screen into a HTS for Rac specific or Rac 
pathway inhibitors, we may uncover potential hits. Also, by using the worm as an in 
vivo tool this early in the drug discovery process we should be able to rapidly deliver 
answers to discovery problems like toxicity or off-target effects, thus improving the 
likelihood of selecting candidates more likely to be successful in further preclinical 
and later clinical evaluation stages. 
 
 
EXAMINATION OF POTENTIAL LEAD COMPOUNDS 
 
It is important to note that the goal of the proposed work is not to study Rac 
function in C. elegans, but to use it as an in vivo platform for drug discovery.  In 
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order to further characterize the activity and selectivity of candidate compounds 
selected from the Rac or Rac pathway inhibitor screen, I would test selected hit 
compounds in a secondary screen, using cell-based assays. Evaluation of our 
candidate compounds in cell-based assays will allow us to determine the potency, 
selectivity and perhaps potential cytotoxic effects caused by these drugs. Moreover, 
testing in cell-based assays will allow the assessment of additional qualities of 
candidate compounds like their ability to alter specific biological effects caused by 
activated Rac, and to determine whether they block at the level of Rac or elsewhere.  
This secondary screen will complement the effects seen in the in vivo studies using 
C. elegans and will support or eliminate some hits based on their properties.  
In order to test the selectivity of hit compounds we need to select endpoints 
that will be accurate for inhibition solely of the Rac pathway. Negative controls 
should include endpoints of neighboring pathway effectors as a way to measure the 
selectivity of each compound for the Rac pathway. One general endpoint is to 
measure the activation of Rac downstream effectors. In the past, our lab has 
evaluated the action of GGTIs towards cells expressing activated Rac1, by using a 
c-Jun luciferase reporter assay (Joyce and Cox, 2003).  c-Jun is a downstream 
target of JNK, which in turn can be activated by Rac1 and Rac-3. To execute this, I 
would transiently transfect NIH3T3 cells with either vector encoding activated 
Rac1(61L) along with a c-jun luciferase reporter, then after 24 h analyze the cell 
lysates for luciferase activity. This cell-based assay would allow me to evaluate 
hundreds of compounds simultaneously, which will be ideal for the first round of 
secondary screen.  However, it will not determine specificity for Rac. 
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If the number of candidate compounds from the primary screen is small (<50), 
an alternate and more selective way to measure the activity of these compounds is 
to visually screen for morphological changes in the cell. Expression of activated 
Rac1 causes the formation of lamellipodia, and our laboratory has shown that 
inhibition of activated Rac1 by GGTI can decrease lamellipodia formation (Joyce and 
Cox, 2003). Based on the ability of other Rac inhibitors to reverse this phenotype, I 
believe I can also use this type of assay to monitor the activity of hit compounds. 
However this procedure will be useful only if there are few hit compounds or at a 
later stage in the evaluation of candidate compounds, since the complex procedures 
to visually prepare the cells for imaging are time consuming, and so it may not be 
useful for the evaluation of hundreds of compounds. 
Overall, I also expect that we can obtain candidate compounds from this 
secondary screen. The detection of positive candidates will be an indication of the 
success of this novel platform for drug discovery. And it is possible that given the 
nature of our primary screen we can obtain candidate compounds that can be further 
evaluated for their advancement to additional pre-clinical studies.  
It is possible that the chemical properties of some of these compounds will 
limit their solubility or bioavailability of each compound to exert its activity. Since the 
primary screen is to be performed in C. elegans, it is possible that candidate 
compounds may have toxic effects in mammalian cells that contain additional 
targets, but this will not be appreciated until we perform these experiments.   The 
assays proposed in this aim will help elucidate the activity of candidate compounds 
towards the Rac pathway, but will not reveal the specific target of selected 
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compounds. To approach this problem, additional biochemical and biological assays 
can be performed.  For example, to address if candidate compounds are targeting 
the kinase activity of PAK, the in vitro kinase activity of PAK can be evaluated. 
Overall we have the tools to develop a reliable and high throughput 
secondary screen. With these ideas I should be able to test the activity of candidate 
compounds to inhibit Rac or the Rac pathway. Moreover, the success of this 
secondary screen will support the generation of additional tools for the screening of 
other clinically relevant targets using the worm as an efficient and valuable in vivo 
model for drug discovery of Ras and Rac pathway inhibitors. 
 
CONCLUSIONS 
 Altogether, my proposed future directions would lead to the development 
of better tools for the analysis of existing inhibitors of the Ras>Raf>MEK>ERK 
pathway and to the rise of a novel platform for the screening of novel Rac or Rac 
pathway inhibitors.  By developing additional transgenic lines harboring new 
Raf/LIN-45 mutants, we would not only be able to further understand the mechanism 
of action of MCP compounds, but also increase the tools available for the evaluation 
of other inhibitors of the Ras>Raf>MEK>ERK pathway.  Despite the wealth of 
genetic reagents freely available in the C. elegans community, there is surprisingly 
no lin-45 mutant suitable for my studies of Ras/Raf interaction inhibitors; nor have I 
been successful to construct one.  If I can develop a successful strategy to do so, 
this would be very useful to the field. 
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  On the other hand, the further development of a high-throughput screen 
for novel Rac pathway inhibitors would showcase a novel approach for drug 
screening in in vivo systems as well as remove one of the problems of screening for 
molecularly targeted therapeutics, which is not knowing the best specific target in a 
given pathway to go after.  The screen I propose is unbiased and should in principle 
identify any functionally useful inhibitor of the pathway. If successful, such a screen 
could potentially be modified for the development of additional screens for other 
cancer-related and validated targets. 
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